

**All Cosmos Bio-Tech Holding Corporation
and Subsidiaries**

**Consolidated Financial Statements for the
Six Months Ended June 30, 2024 and 2023 and
Independent Auditors' Report**

Address: One Nexus Way Camana Bay, Grand
Cayman, KY1-9005 Cayman Islands

Telephone: (607)252-3788

INDEPENDENT AUDITORS' REPORT

The Board of Directors and Shareholders
All Cosmos Bio-Tech Holding Corporation

Opinion

We have audited the accompanying consolidated financial statements of All Cosmos Bio-Tech Holding Corporation (the “Company”) and its subsidiaries (collectively referred to as the “Group”), which comprise the consolidated balance sheets as of June 30, 2024 and 2023, and the consolidated statements of comprehensive income, changes in equity and cash flows for the six months then ended, and notes to the consolidated financial statements, including material accounting policy information (collectively referred to as the “consolidated financial statements”).

In our opinion, the accompanying consolidated financial statements present fairly, in all material respects, the consolidated financial position of the Group as of June 30, 2024 and 2023, and its consolidated financial performance and its consolidated cash flows for the six months then ended in accordance with the Regulations Governing the Preparation of Financial Reports by Securities Issuers, and International Accounting Standard 34 “Interim Financial Reporting endorsed and issued into effect by the Financial Supervisory Commission of the Republic of China.

Basis for Opinion

We conducted our audits in accordance with the Regulations Governing Financial Statement Audit and Attestation Engagements of Certified Public Accountants and the Standards on Auditing of the Republic of China. Our responsibilities under those standards are further described in the Auditors’ Responsibilities for the Audit of the Consolidated Financial Statements section of our report. We are independent of the Group in accordance with The Norm of Professional Ethics for Certified Public Accountant of the Republic of China, and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Key Audit Matters

Key audit matters are those matters that, in our professional judgment, were of most significance in our audit of the consolidated financial statements for the six months ended June 30, 2024. These matters were addressed in the context of our audit of the consolidated financial statements as a whole, and in forming our opinion thereon, and we do not provide a separate opinion on these matters.

The key audit matters identified in the Group's consolidated financial statements for the six months ended June 30, 2024 are stated as follows:

Occurrence of Sales Revenue from Major Customers

The Group primarily focuses on the sale of bioorganic and biochemical compound fertilizers. Considering the higher inherent risk in revenue recognition and its significant impact on the Group's financial statements for major customers whose transaction amounts have significantly increased compared to the same period last year, we identified the occurrence of sales revenue from the aforementioned major customers as the key audit matter.

Refer to Notes 4 (n) and 24 to the consolidated financial statements for details on the accounting policy and relevant disclosures on revenue recognition.

The main audit procedures that we performed in respect of sales revenue from major customers included the following:

1. We obtained an understanding of the Group's internal control and operating procedures of the sales cycle, and we designed the corresponding audit procedures and tested the effectiveness of the internal controls associated with the risk mentioned above.
2. We performed substantive tests on sales revenue, selected samples from the general ledger of sales revenue, and checked the records against external supporting documents and documents of receivables to verify the occurrence of sales.

Responsibilities of Management and Those Charged with Governance for the Consolidated Financial Statements

Management is responsible for the preparation and fair presentation of the consolidated financial statements in accordance with the Regulations Governing the Preparation of Financial Reports by Securities Issuers, and International Accounting Standard 34 "Interim Financial Reporting" endorsed and issued into effect by the Financial Supervisory Commission of the Republic of China, and for such internal control as management determines is necessary to enable the preparation of consolidated financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the consolidated financial statements, management is responsible for assessing the Group's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless management either intends to liquidate the Group or to cease operations, or has no realistic alternative but to do so.

Those charged with governance, including the audit committee, are responsible for overseeing the Group's financial reporting process.

Auditors' Responsibilities for the Audit of the Consolidated Financial Statements

Our objectives are to obtain reasonable assurance about whether the consolidated financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditors' report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with the Standards on Auditing of the Republic of China will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these consolidated financial statements.

As part of an audit in accordance with the Standards on Auditing of the Republic of China, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

1. Identify and assess the risks of material misstatement of the consolidated financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
2. Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Group's internal control.
3. Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by management.
4. Conclude on the appropriateness of management's use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Group's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditors' report to the related disclosures in the consolidated financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditors' report. However, future events or conditions may cause the Group to cease to continue as a going concern.
5. Evaluate the overall presentation, structure and content of the consolidated financial statements, including the disclosures, and whether the consolidated financial statements represent the underlying transactions and events in a manner that achieves fair presentation.
6. Obtain sufficient and appropriate audit evidence regarding the financial information of entities or business activities within the Group to express an opinion on the consolidated financial statements. We are responsible for the direction, supervision, and performance of the group audit. We remain solely responsible for our audit opinion.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

From the matters communicated with those charged with governance, we determine those matters that were of most significance in the audit of the consolidated financial statements for the six months ended June 30, 2024 and are therefore the key audit matters. We describe these matters in our auditors' report unless law or regulation precludes public disclosure about the matter or when, in extremely rare circumstances, we determine that a matter should not be communicated in our report because the adverse consequences of doing so would reasonably be expected to outweigh the public interest benefits of such communication.

The engagement partners on the audits resulting in this independent auditors' report are Cheng-Chuan Yu and Sheng-Tai Liang.

Deloitte & Touche
Taipei, Taiwan
Republic of China

August 27, 2024

Notice to Readers

The accompanying consolidated financial statements are intended only to present the consolidated financial position, financial performance and cash flows in accordance with accounting principles and practices generally accepted in the Republic of China and not those of any other jurisdictions. The standards, procedures and practices to audit such consolidated financial statements are those generally applied in the Republic of China.

For the convenience of readers, the independent auditors' report and the accompanying consolidated financial statements have been translated into English from the original Chinese version prepared and used in the Republic of China. If there is any conflict between the English version and the original Chinese version or any difference in the interpretation of the two versions, the Chinese-language independent auditors' report and consolidated financial statements shall prevail.

ALL COSMOS BIO-TECH HOLDING CORPORATION AND SUBSIDIARIES

CONSOLIDATED BALANCE SHEETS (In Thousands of New Taiwan Dollars)

ASSETS	June 30, 2024		December 31, 2023		June 30, 2023	
	Amount	%	Amount	%	Amount	%
CURRENT ASSETS						
Cash and cash equivalents (Notes 4 and 6)	\$ 1,310,339	35	\$ 1,458,863	40	\$ 1,270,695	35
Financial assets at fair value through profit or loss - current (Notes 4 and 7)	42,734	1	41,071	1	40,036	1
Financial assets at amortized cost - current (Notes 4, 9 and 34)	283,331	8	157,095	4	88,404	2
Trade receivables, net (Notes 4, 10 and 24)	403,776	11	406,014	11	752,816	21
Trade receivables from related parties (Notes 4, 24 and 33)	48,491	1	37,595	1	34,919	1
Other receivables (Notes 4 and 10)	5,229	-	3,706	-	4,504	-
Other receivables from related parties (Notes 4 and 33)	7,118	-	6,698	-	10,948	-
Current tax assets (Note 4)	43,272	1	50,667	2	54,867	2
Inventories (Note 11)	580,910	16	591,062	16	543,785	15
Prepayments (Note 18)	87,511	2	65,212	2	58,087	2
Other current assets (Note 18)	2,184	-	395	-	712	-
Total current assets	<u>2,814,895</u>	<u>75</u>	<u>2,818,378</u>	<u>77</u>	<u>2,859,773</u>	<u>79</u>
NON-CURRENT ASSETS						
Financial assets at fair value through other comprehensive income- non-current (Notes 4 and 8)	4,917	-	-	-	-	-
Investments accounted for using the equity method (Note 13)	24,226	1	22,343	1	18,609	1
Property, plant and equipment (Notes 14 and 34)	717,268	19	641,159	17	561,695	16
Right-of-use assets (Notes 15 and 34)	154,986	4	154,162	4	159,789	4
Goodwill (Note 16)	1,138	-	1,108	-	1,102	-
Other intangible assets (Note 17)	10,012	-	9,072	-	9,059	-
Deferred tax assets (Note 4)	14,030	1	10,737	-	8,956	-
Other non-current assets (Note 18)	11,289	-	16,776	1	15,246	-
Total non-current assets	<u>937,866</u>	<u>25</u>	<u>855,357</u>	<u>23</u>	<u>774,456</u>	<u>21</u>
TOTAL	<u>\$ 3,752,761</u>	<u>100</u>	<u>\$ 3,673,735</u>	<u>100</u>	<u>\$ 3,634,229</u>	<u>100</u>
LIABILITIES AND EQUITY						
CURRENT LIABILITIES						
Short-term borrowings (Notes 19 and 34)	\$ 25,409	1	\$ -	-	\$ -	-
Financial liabilities at fair value through profit or loss - current (Notes 4, 7 and 20)	16,600	-	19,500	-	12,600	1
Contract liabilities - current (Note 24)	2,340	-	907	-	29,571	1
Trade payables	79,815	2	108,530	3	62,301	2
Trade payables to related parties (Note 33)	22,874	1	22,429	1	5,407	-
Other payables (Note 21)	149,553	4	95,794	3	229,165	6
Other payables to related parties (Note 33)	214	-	10,862	-	3	-
Current tax liabilities (Note 4)	25,768	1	18,266	-	38,699	1
Lease liabilities - current (Note 15)	5,398	-	4,760	-	4,985	-
Current portion of long-term borrowings (Notes 19, 20 and 34)	509,365	13	508,446	14	9,601	-
Other current liabilities (Notes 21 and 33)	398	-	751	-	1,050	-
Total current liabilities	<u>837,734</u>	<u>22</u>	<u>790,245</u>	<u>21</u>	<u>393,382</u>	<u>11</u>
NON-CURRENT LIABILITIES						
Bonds payable (Notes 4 and 20)	-	-	-	-	498,178	13
Long-term borrowings (Notes 19 and 34)	20,234	1	24,800	1	29,621	1
Deferred tax liabilities (Note 4)	33,226	1	38,743	1	31,970	1
Lease liabilities - non-current (Note 15)	3,418	-	5,084	-	7,265	-
Net defined benefit liabilities - non-current (Notes 4 and 22)	764	-	669	-	-	-
Total non-current liabilities	<u>57,642</u>	<u>2</u>	<u>69,296</u>	<u>2</u>	<u>567,034</u>	<u>15</u>
Total liabilities	<u>895,376</u>	<u>24</u>	<u>859,541</u>	<u>23</u>	<u>960,416</u>	<u>26</u>
EQUITY ATTRIBUTABLE TO OWNERS OF THE COMPANY (Note 23)						
Share capital						
Ordinary shares	640,340	17	640,340	18	640,340	18
Capital surplus	781,838	21	781,838	21	781,838	21
Retained earnings						
Legal reserve	245,658	6	231,923	6	231,923	6
Special reserve	512,043	14	422,189	12	422,189	12
Unappropriated earnings	558,919	15	690,096	19	630,866	17
Total retained earnings	1,316,620	35	1,344,208	37	1,284,978	35
Other equity	(459,472)	(12)	(512,043)	(14)	(517,844)	(14)
Total equity attributable to owners of the Company	2,279,326	61	2,254,343	62	2,189,312	60
NON-CONTROLLING INTERESTS (Note 23)	<u>578,059</u>	<u>15</u>	<u>559,851</u>	<u>15</u>	<u>484,501</u>	<u>14</u>
Total equity	<u>2,857,385</u>	<u>76</u>	<u>2,814,194</u>	<u>77</u>	<u>2,673,813</u>	<u>74</u>
TOTAL	<u>\$ 3,752,761</u>	<u>100</u>	<u>\$ 3,673,735</u>	<u>100</u>	<u>\$ 3,634,229</u>	<u>100</u>

The accompanying notes are an integral part of the consolidated financial statements.

ALL COSMOS BIO-TECH HOLDING CORPORATION AND SUBSIDIARIES

CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME OR LOSS (In Thousands of New Taiwan Dollars, Except Earnings Per Share)

	For the Three Months Ended June 30				For the Six Months Ended June 30			
	2024		2023		2024		2023	
	Amount	%	Amount	%	Amount	%	Amount	%
OPERATING REVENUE (Notes 24 and 33)								
Sales	\$ 478,391	100	\$ 786,478	100	\$ 1,001,936	100	\$ 1,564,447	100
OPERATING COSTS (Notes 11, 25 and 33)								
Cost of goods sold	<u>(363,106)</u>	<u>(76)</u>	<u>(692,725)</u>	<u>(88)</u>	<u>(747,891)</u>	<u>(75)</u>	<u>(1,319,076)</u>	<u>(84)</u>
GROSS PROFIT	<u>115,285</u>	<u>24</u>	<u>93,753</u>	<u>12</u>	<u>254,045</u>	<u>25</u>	<u>245,371</u>	<u>16</u>
OPERATING EXPENSES (Notes 25 and 33)								
Selling and marketing expenses	(44,195)	(9)	(37,760)	(4)	(87,847)	(9)	(73,761)	(5)
General and administrative expenses	(60,936)	(13)	(53,787)	(7)	(127,314)	(12)	(107,246)	(7)
Research and development expenses	(808)	-	(695)	-	(2,091)	-	(1,013)	-
Expected credit (loss) gain (Notes 10 and 33)	<u>(4,062)</u>	<u>(1)</u>	<u>943</u>	<u>-</u>	<u>(7,740)</u>	<u>(1)</u>	<u>1,469</u>	<u>-</u>
Total operating expenses	<u>(110,001)</u>	<u>(23)</u>	<u>(91,299)</u>	<u>(11)</u>	<u>(224,992)</u>	<u>(22)</u>	<u>(180,551)</u>	<u>(12)</u>
PROFIT FROM OPERATIONS	<u>5,284</u>	<u>1</u>	<u>2,454</u>	<u>1</u>	<u>29,053</u>	<u>3</u>	<u>64,820</u>	<u>4</u>
NON-OPERATING INCOME AND EXPENSES (Notes 25 and 33)								
Interest income	11,892	2	6,047	1	21,746	2	11,995	1
Other income	1,230	-	758	-	10,644	1	2,034	-
Other gains and losses	8,477	2	25,885	3	23,693	3	37,905	3
Finance costs	(1,107)	-	(962)	-	(1,855)	-	(1,812)	-
Share of profit or loss of associates (Note 13)	<u>2,554</u>	<u>1</u>	<u>555</u>	<u>-</u>	<u>1,255</u>	<u>-</u>	<u>1,638</u>	<u>-</u>
Total non-operating income and expenses	<u>23,046</u>	<u>5</u>	<u>32,283</u>	<u>4</u>	<u>55,483</u>	<u>6</u>	<u>51,760</u>	<u>4</u>
PROFIT BEFORE INCOME TAX	28,330	6	34,737	5	84,536	9	116,580	8
INCOME TAX EXPENSE (Notes 4 and 26)	<u>(11,477)</u>	<u>(2)</u>	<u>(5,844)</u>	<u>(1)</u>	<u>(26,758)</u>	<u>(3)</u>	<u>(26,853)</u>	<u>(2)</u>
NET PROFIT FOR THE PERIOD	<u>16,853</u>	<u>4</u>	<u>28,893</u>	<u>4</u>	<u>57,778</u>	<u>6</u>	<u>89,727</u>	<u>6</u>

(Continued)

ALL COSMOS BIO-TECH HOLDING CORPORATION AND SUBSIDIARIES

CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME OR LOSS (In Thousands of New Taiwan Dollars, Except Earnings Per Share)

	For the Three Months Ended June 30				For the Six Months Ended June 30			
	2024		2023		2024		2023	
	Amount	%	Amount	%	Amount	%	Amount	%
OTHER COMPREHENSIVE INCOME (LOSS) (Notes 23 and 26)								
Items that will not be reclassified subsequently to profit or loss:								
Unrealized gain on investments in equity instruments at fair value through other comprehensive income	\$ 195	-	\$ -	-	\$ 195	-	\$ -	-
Exchange differences on translation to the presentation currency	<u>43,065</u>	<u>9</u>	<u>(93,188)</u>	<u>(12)</u>	<u>75,310</u>	<u>7</u>	<u>(124,609)</u>	<u>(8)</u>
Items that may be reclassified subsequently to profit or loss:								
Exchange differences on translation of the financial statements of foreign operations	(11,456)	(2)	7,627	1	(11,387)	(1)	8,977	-
Income tax relating to items that may be reclassified subsequently to profit or loss	<u>2,412</u>	<u>-</u>	<u>(1,793)</u>	<u>-</u>	<u>2,396</u>	<u>-</u>	<u>(2,155)</u>	<u>-</u>
Other comprehensive income (loss) for the period, net of income tax	<u>34,216</u>	<u>7</u>	<u>(87,354)</u>	<u>(11)</u>	<u>66,514</u>	<u>6</u>	<u>(117,787)</u>	<u>(8)</u>
TOTAL COMPREHENSIVE INCOME (LOSS) FOR THE PERIOD	<u>\$ 51,069</u>	<u>11</u>	<u>\$ (58,461)</u>	<u>(7)</u>	<u>\$ 124,292</u>	<u>12</u>	<u>\$ (28,060)</u>	<u>(2)</u>
NET PROFIT								
ATTRIBUTABLE TO:								
Owners of the Company	\$ 7,961	2	\$ 38,868	5	\$ 36,446	4	\$ 79,198	5
Non-controlling interests	<u>8,892</u>	<u>2</u>	<u>(9,975)</u>	<u>(1)</u>	<u>21,332</u>	<u>2</u>	<u>10,529</u>	<u>1</u>
	<u>\$ 16,853</u>	<u>4</u>	<u>\$ 28,893</u>	<u>4</u>	<u>\$ 57,778</u>	<u>6</u>	<u>\$ 89,727</u>	<u>6</u>
TOTAL COMPREHENSIVE INCOME (LOSS) ATTRIBUTABLE TO:								
Owners of the Company	\$ 34,829	7	\$ (31,730)	(4)	\$ 89,017	9	\$ (16,457)	(1)
Non-controlling interests	<u>16,240</u>	<u>4</u>	<u>(26,731)</u>	<u>(3)</u>	<u>35,275</u>	<u>3</u>	<u>(11,603)</u>	<u>(1)</u>
	<u>\$ 51,069</u>	<u>11</u>	<u>\$ (58,461)</u>	<u>(7)</u>	<u>\$ 124,292</u>	<u>12</u>	<u>\$ (28,060)</u>	<u>(2)</u>
EARNINGS PER SHARE (Note 27)								
From continuing operations								
Basic	<u>\$ 0.12</u>		<u>\$ 0.61</u>		<u>\$ 0.57</u>		<u>\$ 1.24</u>	
Diluted	<u>\$ 0.12</u>		<u>\$ 0.42</u>		<u>\$ 0.48</u>		<u>\$ 1.18</u>	

The accompanying notes are an integral part of the consolidated financial statements.

(Concluded)

ALL COSMOS BIO-TECH HOLDING CORPORATION AND SUBSIDIARIES

CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY
(In Thousands of New Taiwan Dollars)

	Equity Attributable to Owners of the Company						Other Equity		Total	Non-controlling Interests	Total Equity
	Share Capital		Capital Surplus	Retained Earnings			Exchange Differences on Translation of the Financial Statements of Foreign Operations	Unrealized Gain on Financial Assets at Fair Value Through Other Comprehensive Income			
	Number of Shares (In Thousands)	Amount		Legal Reserve	Special Reserve	Unappropriated Earnings					
BALANCE AT JANUARY 1, 2023	64,034	\$ 640,340	\$ 781,838	\$ 195,237	\$ 527,952	\$ 643,755	\$ (422,189)	\$ -	\$ 2,366,933	\$ 496,276	\$ 2,863,209
Appropriation of 2022 earnings (Note 23)											
Legal reserve	-	-	-	36,686	-	(36,686)	-	-	-	-	-
Special reserve	-	-	-	-	(105,763)	105,763	-	-	-	-	-
Cash dividends distributed by the Company	-	-	-	-	-	(160,085)	-	-	(160,085)	-	(160,085)
Cash dividends distributed by subsidiaries	-	-	-	-	-	-	-	-	-	(20,360)	(20,360)
Net profit for the six months ended June 30, 2023	-	-	-	-	-	79,198	-	-	79,198	10,529	89,727
Other comprehensive loss for the six months ended June 30, 2023, net of income tax (Note 23)	-	-	-	-	-	-	(95,655)	-	(95,655)	(22,132)	(117,787)
Total comprehensive income (loss) for the six months ended June 30, 2023	-	-	-	-	-	79,198	(95,655)	-	(16,457)	(11,603)	(28,060)
Difference between consideration and carrying amount of subsidiaries acquired (Notes 23 and 28)	-	-	-	-	-	-	-	-	-	19,109	19,109
Change in percentage of ownership interests in subsidiaries (Notes 23 and 29)	-	-	-	-	-	(1,079)	-	-	(1,079)	1,079	-
BALANCE AT JUNE 30, 2023	64,034	\$ 640,340	\$ 781,838	\$ 231,923	\$ 422,189	\$ 630,866	\$ (517,844)	\$ -	\$ 2,189,312	\$ 484,501	\$ 2,673,813
BALANCE AT JANUARY 1, 2024	64,034	\$ 640,340	\$ 781,838	\$ 231,923	\$ 422,189	\$ 690,096	\$ (512,043)	\$ -	\$ 2,254,343	\$ 559,851	\$ 2,814,194
Appropriation of 2023 earnings (Note 23)											
Legal reserve	-	-	-	13,735	-	(13,735)	-	-	-	-	-
Special reserve	-	-	-	-	89,854	(89,854)	-	-	-	-	-
Cash dividends distributed by the Company	-	-	-	-	-	(64,034)	-	-	(64,034)	-	(64,034)
Cash dividends distributed by subsidiaries	-	-	-	-	-	-	-	-	-	(17,067)	(17,067)
Net profit for the six months ended June 30, 2024	-	-	-	-	-	36,446	-	-	36,446	21,332	57,778
Other comprehensive income for the six months ended June 30, 2024, net of income tax (Note 23)	-	-	-	-	-	-	52,376	195	52,571	13,943	66,514
Total comprehensive income for the six months ended June 30, 2024	-	-	-	-	-	36,446	52,376	195	89,017	35,275	124,292
BALANCE AT JUNE 30, 2024	64,034	\$ 640,340	\$ 781,838	\$ 245,658	\$ 512,043	\$ 558,919	\$ (459,667)	\$ 195	\$ 2,279,326	\$ 578,059	\$ 2,857,385

The accompanying notes are an integral part of the consolidated financial statements.

ALL COSMOS BIO-TECH HOLDING CORPORATION AND SUBSIDIARIES

CONSOLIDATED STATEMENTS OF CASH FLOWS (In Thousands of New Taiwan Dollars)

	For the Six Months Ended June 30	
	2024	2023
CASH FLOWS FROM OPERATING ACTIVITIES		
Profit before income tax	\$ 84,536	\$ 116,580
Adjustments for:		
Depreciation expense	24,891	22,785
Amortization expense	705	175
Expected credit loss (gain) reversed on trade receivables	7,740	(1,469)
Net (gain) loss on fair value change of financial assets/liabilities at fair value through profit or loss	(3,939)	3,594
Finance costs	1,855	1,812
Interest income	(21,746)	(11,995)
Share of profit of associates	(1,255)	(1,638)
Gain on disposal of property, plant and equipment	(1,003)	(274)
Net unrealized gain on foreign currency exchange	(16,921)	(12,371)
Changes in operating assets and liabilities		
Financial assets mandatorily classified as at fair value through profit or loss	412	-
Trade receivables	2,861	(121,974)
Trade receivables from related parties	(9,897)	20,463
Other receivables	(62)	49
Inventories	23,262	576,748
Prepayments	(21,176)	6,099
Contract liabilities	1,382	24,489
Trade payables	(31,879)	(12,116)
Trade payables to related parties	(727)	(2,471)
Other payables	(6,310)	(42,536)
Other payables to related parties	(624)	-
Net defined benefit liabilities	101	-
Cash generated from operations	32,206	565,950
Interest received	20,097	9,851
Interest paid	(1,319)	(1,812)
Income tax paid	(18,477)	(78,815)
Net cash generated from operating activities	32,507	495,174
CASH FLOWS FROM INVESTING ACTIVITIES		
Purchase of financial assets at amortized cost	(119,752)	-
Proceeds from sale of financial assets at amortized cost	-	33,605
Purchase of financial assets at fair value through profit or loss	(10,028)	(41,084)
Proceeds from sale of financial assets at fair value through profit or loss	10,113	-
Purchase of financial assets at fair value through other comprehensive income	(4,632)	-
Purchase of subsidiaries	-	29,638

(Continued)

ALL COSMOS BIO-TECH HOLDING CORPORATION AND SUBSIDIARIES

CONSOLIDATED STATEMENTS OF CASH FLOWS (In Thousands of New Taiwan Dollars)

	For the Six Months Ended June 30	
	2024	2023
Payments for property, plant and equipment	\$ (102,173)	\$ (81,746)
Proceeds from disposal of property, plant and equipment	1,059	274
Increase in refundable deposits	(446)	-
Decrease in refundable deposits	-	2,402
Decrease in other receivables from related parties	321	15
Payments for intangible assets	(1,118)	(145)
Increase in prepayment for equipment	-	(5,186)
Decrease in prepayment for equipment	<u>2,335</u>	<u>-</u>
Net cash used in investing activities	<u>(224,321)</u>	<u>(62,227)</u>
CASH FLOWS FROM FINANCING ACTIVITIES		
Proceeds from short-term borrowings	43,439	-
Repayments of short-term borrowings	(17,867)	(387,547)
Repayments of long-term borrowings	(4,902)	(4,791)
Proceeds from guarantee deposits received	42	287
Increase in other payables to related parties	413	3
Repayment of the principal portion of lease liabilities	(2,656)	(3,483)
Dividends paid to non-controlling interests	<u>(17,067)</u>	<u>(20,360)</u>
Net cash generated from (used in) financing activities	<u>1,402</u>	<u>(415,891)</u>
EFFECTS OF EXCHANGE RATE CHANGES ON THE BALANCE OF CASH HELD IN FOREIGN CURRENCIES	<u>41,888</u>	<u>(87,871)</u>
NET DECREASE IN CASH AND CASH EQUIVALENTS	(148,524)	(70,815)
CASH AND CASH EQUIVALENTS AT THE BEGINNING OF THE PERIOD	<u>1,458,863</u>	<u>1,341,510</u>
CASH AND CASH EQUIVALENTS AT THE END OF THE PERIOD	<u>\$ 1,310,339</u>	<u>\$ 1,270,695</u>

The accompanying notes are an integral part of the consolidated financial statements.

(Concluded)

ALL COSMOS BIO-TECH HOLDING CORPORATION AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS FOR THE SIX MONTHS ENDED JUNE 30, 2024 AND 2023 (In Thousands of New Taiwan Dollars, Unless Stated Otherwise)

1. GENERAL INFORMATION

All Cosmos Bio-Tech Holding Corporation (the “Company”) is a limited company incorporated in the Cayman Islands on March 26, 2010. The Company and its subsidiaries (collectively referred to as the “Group”) have reorganized in order to list the Company’s shares on the Taiwan Stock Exchange. On June 1, 2010, the Company issued new shares for 100% equity interest in All Cosmos Industries Sdn. Bhd. and completed the Group’s investment process. The major operating activities of the Group are the production and sale of Bio-organic and Bio-chemical compound fertilizers.

The Company’s shares have been listed on the Taiwan Stock Exchange since June 2017.

The functional currency of the Company is the Malaysian Ringgit. For greater comparability and consistency of financial reporting, the consolidated financial statements are presented in New Taiwan dollars since the Company’s shares are listed on the Taiwan Stock Exchange.

2. APPROVAL OF FINANCIAL STATEMENTS

The consolidated financial statements were approved by the Company’s board of directors on August 27, 2024.

3. APPLICATION OF NEW, AMENDED AND REVISED STANDARDS AND INTERPRETATIONS

- a. Initial application of the amendments to the International Financial Reporting Standards (IFRS), International Accounting Standards (IAS), IFRIC Interpretations (IFRIC), and SIC Interpretations (SIC) (collectively, the “IFRS Accounting Standards”) endorsed and issued into effect by the Financial Supervisory Commission of the Republic of China (FSC)

The initial application of the IFRS Accounting Standards endorsed and issued into effect by the FSC did not have a material impact on the Group’s accounting policies.

- b. The IFRS Accounting Standards endorsed by the FSC for application starting from 2025

New, Amended and Revised Standards and Interpretations	Effective Date Announced by International Accounting Standards Board (IASB)
Amendments to IAS 21 “Lack of Exchangeability”	January 1, 2025 (Note)

Note: An entity shall apply those amendments for annual reporting periods beginning on or after January 1, 2025. Upon initial application of the amendments to IAS 21, the Group shall not restate the comparative information and shall recognize any effect of initially applying the amendments as an adjustment to the opening balance of retained earnings or, if applicable, to the cumulative amount of translation differences in equity as well as affected assets or liabilities.

As of the date the consolidated financial statements were authorized for issue, the Group is continuously assessing the possible impact of the application of other standards and interpretations on the Group's financial position and financial performance and will disclose the relevant impact when the assessment is completed.

- c. The IFRS Accounting Standards in issue but not yet endorsed and issued into effect by the FSC

<u>New, Amended and Revised Standards and Interpretations</u>	<u>Effective Date Announced by IASB (Note)</u>
Annual Improvements to IFRS Accounting Standards - Volume 11	January 1, 2026
Amendments to IFRS 9 and IFRS 7 "Amendments to the Classification and Measurement of Financial Instruments"	January 1, 2026
Amendments to IFRS 10 and IAS 28 "Sale or Contribution of Assets between an Investor and its Associate or Joint Venture"	To be determined by IASB
IFRS 17 "Insurance Contracts"	January 1, 2023
Amendments to IFRS 17	January 1, 2023
Amendments to IFRS 17 "Initial Application of IFRS 17 and IFRS 9 - Comparative Information"	January 1, 2023
IFRS 18 "Presentation and Disclosure in Financial Statements"	January 1, 2027
IFRS 19 "Subsidiaries without Public Accountability: Disclosures"	January 1, 2027

Note: Unless stated otherwise, the above IFRS Accounting Standards will be effective for annual reporting periods beginning on or after their respective effective dates.

IFRS 18 "Presentation and Disclosure in Financial Statements"

IFRS 18 will supersede IAS 1 "Presentation of Financial Statements". The main changes comprise:

- Items of income and expenses included in the statement of profit or loss shall be classified into the operating, investing, financing, income taxes and discontinued operations categories.
- The statement of profit or loss shall present totals and subtotals for operating profit or loss, profit or loss before financing and income taxes and profit or loss.
- Provides guidance to enhance the requirements of aggregation and disaggregation: The Group shall identify the assets, liabilities, equity, income, expenses and cash flows that arise from individual transactions or other events and shall classify and aggregate them into groups based on shared characteristics, so as to result in the presentation in the primary financial statements of line items that have at least one similar characteristic. The Group shall disaggregate items with dissimilar characteristics in the primary financial statements and in the notes. The Group labels items as "other" only if it cannot find a more informative label.
- Disclosures on Management-defined Performance Measures (MPMs): When in public communications outside financial statements and communicating to users of financial statements management's view of an aspect of the financial performance of the Group as a whole, the Group shall disclose related information about its MPMs in a single note to the financial statements, including the description of such measures, calculations, reconciliations to the subtotal or total specified by IFRS Accounting Standards and the income tax and non-controlling interests effects of related reconciliation items.

Except for the above impact, as of the date the consolidated financial statements were authorized for issue, the Group is continuously assessing other impacts of the above amended standards and interpretations on the Group's financial position and financial performance and will disclose the relevant impact when the assessment is completed.

4. SUMMARY OF MATERIAL ACCOUNTING POLICY INFORMATION

For the convenience of readers, the accompanying consolidated financial statements have been translated into English from the original Chinese version prepared and used in the Republic of China. If there is any conflict between the English version and the original Chinese version or any difference in the interpretation of the two versions, the Chinese-language consolidated financial statements shall prevail.

a. Statement of compliance

These interim consolidated financial statements have been prepared in accordance with the Regulations Governing the Preparation of Financial Reports by Securities Issuer and IAS 34 "Interim Financial Reporting" as endorsed and issued into effect by the FSC. Disclosure information included in these interim consolidated financial statements is less than the disclosure information required in a complete set of annual consolidated financial statements.

b. Basis of preparation

The consolidated financial statements have been prepared on the historical cost basis except for financial instruments which are measured at fair value and net defined benefit liabilities which are measured at the present value of the defined benefit obligation less the fair value of plan assets.

The fair value measurements, which are grouped into Levels 1 to 3 based on the degree to which the fair value measurement inputs are observable and based on the significance of the inputs to the fair value measurement in its entirety, are described as follows:

- 1) Level 1 inputs are quoted prices (unadjusted) in active markets for identical assets or liabilities;
- 2) Level 2 inputs are inputs other than quoted prices included within Level 1 that are observable for an asset or liability, either directly (i.e., as prices) or indirectly (i.e., derived from prices); and
- 3) Level 3 inputs are unobservable inputs for an asset or liability.

c. Basis of consolidation

The consolidated financial statements incorporate the financial statements of the Company and the entities controlled by the Company (i.e., its subsidiaries). Income and expenses of subsidiaries acquired or disposed of during the period are included in the consolidated statement of comprehensive income from the effective dates of acquisitions up to the effective dates of disposals, as appropriate. When necessary, adjustments are made to the financial statements of subsidiaries to bring their accounting policies into line with those of the Group. All intra-group transactions, balances, income and expenses are eliminated in full upon consolidation. Total comprehensive income of subsidiaries is attributed to the owners of the Company and to the non-controlling interests even if this results in the non-controlling interests having a deficit balance.

Changes in the Group's ownership interests in subsidiaries that do not result in the Group losing control over the subsidiaries are accounted for as equity transactions. The carrying amounts of the interests of the Group and the non-controlling interests are adjusted to reflect the changes in their relative interests in the subsidiaries. Any difference between the amount by which the non-controlling interests are adjusted and the fair value of the consideration paid or received is recognized directly in equity and attributed to the owners of the Company.

Refer to Note 12 and Table 7 for detailed information on subsidiaries (including percentages of ownership and main businesses).

d. Other material accounting policies

Except for the following paragraphs, refer to the consolidated financial statements for the year ended December 31, 2023.

1) Classification of current and non-current assets and liabilities

Current assets include:

- a) Assets held primarily for the purpose of trading;
- b) Assets expected to be realized within 12 months after the reporting period; and
- c) Cash and cash equivalents unless the asset is restricted from being exchanged or used to settle a liability for at least 12 months after the reporting period.

Current liabilities include:

- a) Liabilities held primarily for the purpose of trading;
- b) Liabilities due to be settled within 12 months after the reporting period; and
- c) Liabilities for which the Group does not have the substantial right at the end of the reporting period to defer settlement for at least 12 months after the reporting period.

Assets and liabilities that are not classified as current are classified as non-current.

2) Financial instruments

Financial assets and financial liabilities are recognized when the Group becomes a party to the contractual provisions of the instruments.

Financial assets and financial liabilities are initially measured at fair value. Transaction costs that are directly attributable to the acquisition or issuance of financial assets and financial liabilities (other than financial assets and financial liabilities at fair value through profit or loss) are added to or deducted from the fair value of the financial assets or financial liabilities, as appropriate, on initial recognition. Transaction costs directly attributable to the acquisition of financial assets or financial liabilities at fair value through profit or loss (i.e., FVTPL) are recognized immediately in profit or loss.

a) Financial assets

All regular way purchases or sales of financial assets are recognized and derecognized on a trade date basis.

i. Measurement categories

Financial assets are classified into the following categories: Financial assets at FVTPL, financial assets at amortized cost and investments in equity instruments at fair value through other comprehensive income (i.e., FVTOCI).

i) Financial assets at FVTPL

Financial assets are classified as at FVTPL when such a financial asset is mandatorily classified as at FVTPL. Financial assets mandatorily classified as at FVTPL include investments in equity instruments which are not designated as at FVTOCI and debt instruments that do not meet the amortized cost criteria or the FVTOCI criteria.

Financial assets at FVTPL are subsequently measured at fair value, and any dividends, interest earned on such financial assets are recognized in other income; any remeasurement gains or losses on such financial assets are recognized in other gains or losses. Fair value is determined in the manner described in Note 32 “Financial Instruments”.

ii) Financial assets at amortized cost

Financial assets that meet the following conditions are subsequently measured at amortized cost:

- The financial asset is held within a business model whose objective is to hold financial assets in order to collect contractual cash flows; and
- The contractual terms of the financial asset give rise on specified dates to cash flows that are solely payments of principal and interest on the principal amount outstanding.

Subsequent to initial recognition, financial assets at amortized cost, including cash and cash equivalents, trade receivables at amortized cost and refundable deposits, are measured at amortized cost, which equals the gross carrying amount determined using the effective interest method less any impairment loss. Exchange differences are recognized in profit or loss.

Interest income is calculated by applying the effective interest rate to the gross carrying amount of such a financial asset, except for:

- Purchased or originated credit-impaired financial assets, for which interest income is calculated by applying the credit-adjusted effective interest rate to the amortized cost of such financial assets; and
- Financial assets that are not credit impaired on purchase or origination but have subsequently become credit impaired, for which interest income is calculated by applying the effective interest rate to the amortized cost of such financial assets in subsequent reporting periods.

iii) A financial asset is credit impaired when one or more of the following events have occurred:

- Significant financial difficulty of the issuer or the borrower;
- Breach of contract, such as a default;

- It is becoming probable that the borrower will enter bankruptcy or undergo a financial reorganization; or
- The disappearance of an active market for that financial asset because of financial difficulties.

Cash equivalents include time deposits with original maturities within 3 months from the date of acquisition, which are highly liquid, readily convertible to a known amount of cash and are subject to an insignificant risk of changes in value. These cash equivalents are held for the purpose of meeting short-term cash commitments.

ii. Investments in equity instruments at FVTOCI

On initial recognition, the Group may make an irrevocable election to designate investments in equity instruments as at FVTOCI. Designation as at FVTOCI is not permitted if the equity investment is held for trading or if it is contingent consideration recognized by an acquirer in a business combination.

Investments in equity instruments at FVTOCI are subsequently measured at fair value with gains and losses arising from changes in fair value recognized in other comprehensive income and accumulated in other equity. The cumulative gain or loss will not be reclassified to profit or loss on disposal of the equity investments; instead, it will be transferred to retained earnings.

Dividends on these investments in equity instruments are recognized in profit or loss when the Group's right to receive the dividends is established, unless the dividends clearly represent a recovery of part of the cost of the investment.

iii. Impairment of financial assets

The Group recognizes a loss allowance for expected credit losses (ECLs) on financial assets at amortized cost (including trade receivables).

The Group always recognizes lifetime ECLs for trade receivables. For all other financial instruments, the Group recognizes lifetime ECLs when there has been a significant increase in credit risk since initial recognition. If, on the other hand, the credit risk on a financial instrument has not increased significantly since initial recognition, the Group measures the loss allowance for that financial instrument at an amount equal to 12-month ECLs.

Expected credit losses reflect the weighted average of credit losses with the respective risks of default occurring as the weights. Lifetime ECLs represent the expected credit losses that will result from all possible default events over the expected life of a financial instrument. In contrast, 12-month ECLs represent the portion of lifetime ECLs that is expected to result from default events on a financial instrument that are possible within 12 months after the reporting date.

For internal credit risk management purposes, the Group considers the following situations as indication that a financial asset is in default (without taking into account any collateral held by the Group):

- i) Internal or external information show that the debtor is unlikely to pay its creditors.
- ii) Financial asset is more than 270 days past due unless the Group has reasonable and corroborative information to support a more lagged default criterion.

The impairment loss of all financial assets is recognized in profit or loss by a reduction in their carrying amounts through a loss allowance account.

iv. Derecognition of financial assets

The Group derecognizes a financial asset only when the contractual rights to the cash flows from the asset expire or when it transfers the financial asset and substantially all the risks and rewards of ownership of the asset to another party.

On derecognition of a financial asset at amortized cost in its entirety, the difference between the asset's carrying amount and the sum of the consideration received and receivable is recognized in profit or loss.

b) Financial liabilities

i. Subsequent measurement

Except the following situation, all financial liabilities are measured at amortized cost using the effective interest method.

Financial liabilities at FVTPL

Financial liabilities held by the Group are held for trading. Financial liabilities held for trading are stated at fair value, and any interest paid on such financial liabilities is recognized in finance costs; any remeasurement gains and losses on such financial liabilities are recognized in other gains or losses.

Fair value is determined in the manner described in Note 32.

ii. Derecognition of financial liabilities

The difference between the carrying amount of a financial liability derecognized and the consideration paid, including any non-cash assets transferred or liabilities assumed, is recognized in profit or loss.

c) Convertible bonds

The conversion option component of the convertible bonds issued by the Group, which will be settled other than by the exchange of a fixed amount of cash or other financial assets for a fixed number of the Company's own equity instruments, is classified as a derivative financial liability.

On initial recognition, the derivative financial liability component of the convertible bonds is recognized at fair value, and the initial carrying amount of the non-derivative financial liability component is determined by deducting the amount of the derivative financial liability component from the fair value of the hybrid instrument as a whole. In subsequent periods, the non-derivative financial liability component of the convertible bonds is measured at amortized cost using the effective interest method. The derivative financial liability component is measured at fair value, and the changes in fair value are recognized in profit or loss. Transaction costs that relate to the issuance of the convertible notes are allocated to the derivative financial liability component and the non-derivative financial liability component in proportion to their relative fair values. Transaction costs relating to the derivative financial liability component are recognized immediately in profit or loss. Transaction costs relating to the non-derivative financial liability component are included in the carrying amount of the liability component.

d) Derivative financial instruments

The Group enters into a variety of derivative financial instruments to manage its exposure to foreign exchange rate risks, including foreign exchange forward contracts.

Derivatives are initially recognized at fair value at the date on which the derivative contracts are entered into and are subsequently remeasured to their fair value at the end of each reporting period. The resulting gain or loss is recognized in profit or loss immediately unless the derivative is designated and effective as a hedging instrument; in which event, the timing of the recognition in profit or loss depends on the nature of the hedging relationship. When the fair value of a derivative financial instrument is positive, the derivative is recognized as a financial asset; when the fair value of a derivative financial instrument is negative, the derivative is recognized as a financial liability.

3) Retirement benefits

Pension cost for an interim period is calculated on a year-to-date basis by using the actuarially determined pension cost rate at the end of the prior financial year, adjusted for significant market fluctuations since that time and for significant plan amendments, settlements, or other significant one-off events.

4) Income tax expense

Income tax expense represents the sum of the tax currently payable and deferred tax. Interim period income taxes are assessed on an annual basis and calculated by applying to an interim period's pre-tax income the tax rate that would be applicable to expected total annual earnings.

5. MATERIAL ACCOUNTING JUDGMENTS AND KEY SOURCES OF ESTIMATION UNCERTAINTY

The same material accounting judgments and key sources of estimation and uncertainty have been followed in these consolidated financial statements as were applied in the preparation of the consolidated financial statements for the year ended December 31, 2023.

6. CASH AND CASH EQUIVALENTS

	June 30, 2024	December 31, 2023	June 30, 2023
Cash on hand	\$ 449	\$ 442	\$ 355
Checking accounts and demand deposits	1,046,640	1,079,188	922,376
Cash equivalent			
Time deposits (with original maturities of 3 months or less)	<u>263,250</u>	<u>379,233</u>	<u>347,964</u>
	<u>\$ 1,310,339</u>	<u>\$ 1,458,863</u>	<u>\$ 1,270,695</u>

The market rate intervals of cash in bank at the end of the year were as follows:

	June 30, 2024	December 31, 2023	June 30, 2023
Time deposits (with original maturities of 3 months or less)	3.10%-5.42%	2.75%-5.60%	2.70%-4.20%

7. FINANCIAL INSTRUMENTS AT FVTPL

	June 30, 2024	December 31, 2023	June 30, 2023
<u>Financial assets at FVTPL - current</u>			
Financial assets mandatorily classified as at FVTPL			
Derivative financial assets (not under hedge accounting)			
Foreign exchange forward contracts	\$ -	\$ 149	\$ -
Non-derivative financial assets			
Mutual funds	<u>42,734</u>	<u>40,922</u>	<u>40,036</u>
	<u>\$ 42,734</u>	<u>\$ 41,071</u>	<u>\$ 40,036</u>

Financial liabilities at FVTPL - current

Financial liabilities held for trading			
Derivative financial liabilities (not under hedge accounting)			
Convertible options (Note 20)	<u>\$ 16,600</u>	<u>\$ 19,500</u>	<u>\$ 12,600</u>

At the end of the reporting period, outstanding foreign exchange forward contracts not under hedge accounting were as follows:

	Currency	Maturity Date	Notional Amount (In Thousands)
<u>December 31, 2023</u>			
Buy	USD/MYR	January 22, 2024	USD100/MYR465
Buy	USD/MYR	January 22, 2024	USD100/MYR462
Buy	USD/MYR	January 26, 2024	USD100/MYR461

8. FINANCIAL ASSETS AT FAIR VALUE THROUGH OTHER COMPREHENSIVE INCOME

	June 30, 2024	December 31, 2023	June 30, 2023
<u>Investments in equity instruments - non-current</u>			
Domestic investments			
Unlisted shares	<u>\$ 4,917</u>	<u>\$ -</u>	<u>\$ -</u>

These investments in equity instruments are held for medium- to long-term strategic purposes. Accordingly, the management elected to designate these investments in equity instruments as at FVTOCI as they believe that recognizing short-term fluctuations in these investments' fair value in profit or loss would not be consistent with the Group's strategy of holding these investments for long-term purposes.

9. FINANCIAL ASSETS AT AMORTIZED COST

	June 30, 2024	December 31, 2023	June 30, 2023
<u>Current</u>			
Time deposits with original maturities of more than 3 months	\$ 156,580	\$ 71,065	\$ 4,112
Restricted bank deposits (a)	<u>126,751</u>	<u>86,030</u>	<u>84,292</u>
	<u>\$ 283,331</u>	<u>\$ 157,095</u>	<u>\$ 88,404</u>

Market rate intervals

Time deposits with original maturities of more than 3 months	2.50%-5.40%	3.10%-4.00%	3.10%-4.30%
Restricted bank deposits	2.00%-3.05%	2.00%-3.10%	1.90%-2.85%

- a. Refer to Note 34 for information relating to the restricted time deposits pledged as collaterals for borrowings by the Group.
- b. The Group's exposure and the external credit ratings are continuously monitored. The Group reviews changes in bond yields and other publicly available information and makes an assessment whether there has been a significant increase in credit risk since the last period to the reporting date. After the assessment, the Group estimates that there were no expected credit losses on the financial assets at amortized cost.

10. TRADE RECEIVABLES AND OTHER RECEIVABLES

	June 30, 2024	December 31, 2023	June 30, 2023
<u>Trade receivables</u>			
At amortized cost			
Gross carrying amount	\$ 419,351	\$ 413,714	\$ 761,191
Less: Allowance for impairment loss	<u>(15,575)</u>	<u>(7,700)</u>	<u>(8,375)</u>
	<u>\$ 403,776</u>	<u>\$ 406,014</u>	<u>\$ 752,816</u>
<u>Other receivables</u>			
Interest receivables	\$ 3,688	\$ 2,266	\$ 2,867
GST refund receivables	-	-	164
Others	<u>1,541</u>	<u>1,440</u>	<u>1,473</u>
	<u>\$ 5,229</u>	<u>\$ 3,706</u>	<u>\$ 4,504</u>

a. Trade receivables

The average credit period of sales of goods is 60 to 90 days. No interest is charged on trade receivables. The Group adopted a policy of only dealing with entities that are rated the equivalent of investment grade or higher and obtaining sufficient collateral, where appropriate, as a means of mitigating the risk of financial loss from defaults. The Group uses other publicly available financial information or its own trading records to rate its major customers.

The Group measures the loss allowance for trade receivables at an amount equal to lifetime ECLs. The ECLs on trade receivables are estimated using a provision matrix prepared by reference to the past default records of the customer, the customer's current financial position as well as the GDP forecasts. As the Group's historical credit loss experience does not show significantly different loss patterns for different customer segments, the provision for loss allowance based on past due status is not further distinguished according to the Group's different customer base.

The Group writes off its trade receivable in the event of when there is evidence indicating that particular receivable is in severe financial difficulty and there is no realistic prospect of recovery. For those trade receivable written off, the Group continues to engage in enforcement activity to attempt to recover the outstanding. A reversal of bad debts is recognized in profit or loss when recovery is made.

The following table details the loss allowance of trade receivables based on the Group's provision matrix:

June 30, 2024

	Not Past Due	1 to 90 Days Past Due	91 to 180 Days Past Due	181 to 270 Days Past Due	Over 270 Days Past Due	Total
Expected credit loss rate	0.004%-0.56%	0.05%-3.31%	0.45%-17.58%	6.76%-39.40%	100.00%	
Gross carrying amount	\$ 284,248	\$ 108,692	\$ 11,505	\$ 3,918	\$ 10,988	\$ 419,351
Loss allowance (Lifetime ECLs)	<u>(945)</u>	<u>(1,454)</u>	<u>(771)</u>	<u>(1,417)</u>	<u>(10,988)</u>	<u>(15,575)</u>
Amortized cost	<u>\$ 283,303</u>	<u>\$ 107,238</u>	<u>\$ 10,734</u>	<u>\$ 2,501</u>	<u>\$ -</u>	<u>\$ 403,776</u>

December 31, 2023

	Not Past Due	1 to 90 Days Past Due	91 to 180 Days Past Due	181 to 270 Days Past Due	Over 270 Days Past Due	Total
Expected credit loss rate	0.05%-0.44%	0.41%-2.40%	3.50%-9.74%	16.67%-25.82%	100.00%	
Gross carrying amount	\$ 297,387	\$ 99,003	\$ 9,290	\$ 4,041	\$ 3,993	\$ 413,714
Loss allowance (Lifetime ECLs)	<u>(766)</u>	<u>(1,395)</u>	<u>(567)</u>	<u>(979)</u>	<u>(3,993)</u>	<u>(7,700)</u>
Amortized cost	<u>\$ 296,621</u>	<u>\$ 97,608</u>	<u>\$ 8,723</u>	<u>\$ 3,062</u>	<u>\$ -</u>	<u>\$ 406,014</u>

June 30, 2023

	Not Past Due	1 to 90 Days Past Due	91 to 180 Days Past Due	181 to 270 Days Past Due	Over 270 Days Past Due	Total
Expected credit loss rate	0.02%-0.36%	0.18%-1.62%	1.35%-5.81%	9.02%-15.64%	100.00%	
Gross carrying amount	\$ 612,989	\$ 96,766	\$ 35,423	\$ 12,189	\$ 3,824	\$ 761,191
Loss allowance (Lifetime ECLs)	<u>(1,376)</u>	<u>(790)</u>	<u>(512)</u>	<u>(1,873)</u>	<u>(3,824)</u>	<u>(8,375)</u>
Amortized cost	<u>\$ 611,613</u>	<u>\$ 95,976</u>	<u>\$ 34,911</u>	<u>\$ 10,316</u>	<u>\$ -</u>	<u>\$ 752,816</u>

The movements of the loss allowance of trade receivables were as follows:

	For the Six Months Ended June 30	
	2024	2023
Balance at January 1	\$ 7,700	\$ 10,268
Add: Net provision of loss allowance	7,541	-
Less: Net remeasurement of loss allowance	-	(1,481)
Foreign exchange translation differences	<u>334</u>	<u>(412)</u>
Balance at June 30	<u>\$ 15,575</u>	<u>\$ 8,375</u>

b. Other receivables

Other receivables primarily included interest receivables and others. The Group continuously monitors past default experience of the counterparties and analyzes their current financial position. Based on the aforementioned information, the Group then assesses the expected credit loss and considers whether credit risk has significantly increased from the last period to the reporting date. As of June 30, 2024, December 31, 2023 and June 30, 2023, the Group estimates that there was no expected credit loss on other receivables.

11. INVENTORIES

	June 30, 2024	December 31, 2023	June 30, 2023
Merchandise	\$ 80,461	\$ 29,490	\$ 42,324
Finished goods	57,743	48,979	84,322
Work in progress	11,006	6,806	7,742
Raw materials	370,910	400,771	382,775
Inventory in transit	<u>60,790</u>	<u>105,016</u>	<u>26,622</u>
	<u>\$ 580,910</u>	<u>\$ 591,062</u>	<u>\$ 543,785</u>

The cost of inventories recognized as cost of goods sold for the three months ended June 30, 2024 and 2023 was \$363,106 thousand and \$692,725 thousand, respectively, and the cost of inventories recognized as cost of goods sold for the six months ended June 30, 2024 and 2023 was \$747,891 thousand and \$1,319,076 thousand, respectively.

12. SUBSIDIARIES

a. Subsidiaries included in the consolidated financial statements

Investor	Investee	Nature of Activities	Proportion of Ownership (%)			Remark
			June 30, 2024	December 31, 2023	June 30, 2023	
The Company	All Cosmos Industries Sdn. Bhd.	Manufacturing and sales of Bio-organic and Bio-chemical compound fertilizers	100	100	100	
	Sabah Softwoods Hybrid Fertiliser Sdn. Bhd.	Manufacturing and sales of Bio-organic and Bio-chemical compound fertilizers	55	55	55	
	PT All Cosmos Indonesia	Sales of Bio-organic and Bio-chemical compound fertilizers	99	99	99	
	PT All Cosmos Biotek	Manufacturing and sales of Bio-organic and Bio-chemical compound fertilizers	83	83	95	Note 2
	GK Bio International Sdn. Bhd.	Wholesale of probiotics	60	60	60	

(Continued)

Investor	Investee	Nature of Activities	Proportion of Ownership (%)			Remark
			June 30, 2024	December 31, 2023	June 30, 2023	
All Cosmos Industries Sdn. Bhd.	PT All Cosmos Indonesia	Sales of Bio-organic and Bio-chemical compound fertilizers	1	1	1	
	Arif Efektif Sdn. Bhd.	Research and development of effective microorganisms for Bio-organic and Bio-chemical compound fertilizers	49	49	49	Note 1
	Kinabalu Life Sciences Sdn. Bhd.	Research and development of effective microorganisms for waste disposal of oil-palm	60	60	60	
	Cosmos Nutriscience Sdn. Bhd., formerly known as Cosmos Biowood Sdn. Bhd.	Manufacture and sale of health care food and biotechnology research and development	92	92	80	Note 4
	Eastern Eckare Malaysia Sdn. Bhd.	Sales of health care food and cosmetics	60	60	60	Note 3

(Concluded)

Note 1: The Group and its substantive related party separately hold 49% and 31% interest in Arif Efektif Sdn. Bhd. Their combined holding shares exceed 50% of the total shares outstanding. Hence, the Group has substantive control over Arif Efektif Sdn. Bhd. and has included it as part of the Group.

Note 2: In February 2023 and March 2023, the Company subscribed for new shares issued by PT All Cosmos Biotek (PTACB) at a percentage different from its existing ownership proportion, which increased its continuing interest of US\$1,800 thousand (equivalent to IDR24,816,289 thousand) and US\$2,000 thousand (equivalent to IDR27,573,655 thousand), respectively. The Company's proportion of ownership in PTACB increased to 95% in March 2023. However, in October 2023, PTACB increased its capital by IDR15,915,000 thousand with all shares subscribed by its non-controlling interest shareholder, YPJ Plantations Sdn. Bhd. (YPJ), which resulted in a decrease of the Company's shareholding to 83%. However, it did not affect the Company's control over PTACB.

Note 3: On August 1, 2022, the Company's subsidiary, All Cosmos Industries Sdn. Bhd. (ACI), signed a shareholder agreement with Eastern E-Commerce Co., Ltd. to jointly establish Eckare Malaysia Sdn. Bhd. (EEMSB). The amounts of issued capital made by both parties were MYR2,000 thousand and MYR3,000 thousand, respectively.

In April 2023, EEMSB issued new shares for cash of MYR2,500 thousand, and ACI subscribed for all at a percentage different from its existing ownership proportion. The Group's proportion of ownership increased from 40% to 60%, and the Group is able to obtain control over EEMSB. Therefore, EEMSB has been one of the Group's components since April 2023. Refer to Note 28 for the aforementioned equity transaction.

Note 4: In October 2023, ACI injected cash of MYR800 thousand into its subsidiary, Cosmos Nutriscience Sdn. Bhd. (formerly known as Cosmos Biowood Sdn. Bhd.), at a percentage different from its existing ownership proportion, and the registration for the issuance of shares was completed.

b. Details of subsidiaries that have material non-controlling interests

Name of Subsidiary	Proportion of Ownership and Voting Rights Held by Non-controlling Interests		
	June 30, 2024	December 31, 2023	June 30, 2023
Sabah Softwoods Hybrid Fertiliser Sdn. Bhd.	45%	45%	45%

Refer to Table 7 for the information on the principal places of business and the countries of incorporation.

Name of Subsidiary	Profit Allocated to Non-controlling Interests		Accumulated Non-controlling Interests		
	For the Six Months Ended June 30		December 31,		
	2024	2023	June 30, 2024	2023	June 30, 2023
Sabah Softwoods Hybrid Fertiliser Sdn. Bhd.	\$ 15,118	\$ 2,803	\$ 388,858	\$ 378,695	\$ 354,668

Summarized financial information of the subsidiary that has material non-controlling interests is set out below. The summarized financial information below represents amounts before intragroup eliminations.

Sabah Softwoods Hybrid Fertiliser Sdn. Bhd.

	June 30, 2024	December 31, 2023	June 30, 2023
Current assets	\$ 674,568	\$ 706,032	\$ 608,731
Non-current assets	246,614	241,968	238,710
Current liabilities	(41,763)	(90,029)	(44,194)
Non-current liabilities	<u>(15,289)</u>	<u>(16,427)</u>	<u>(15,096)</u>
Equity	<u>\$ 864,130</u>	<u>\$ 841,544</u>	<u>\$ 788,151</u>
Equity attributable to:			
The Company	\$ 475,272	\$ 462,849	\$ 433,483
Non-controlling interests	<u>388,858</u>	<u>378,695</u>	<u>354,668</u>
	<u>\$ 864,130</u>	<u>\$ 841,544</u>	<u>\$ 788,151</u>
		For the Six Months Ended June 30	
		2024	2023
Revenue		<u>\$ 288,557</u>	<u>\$ 445,778</u>
Profit for the period		\$ 33,595	\$ 6,229
Other comprehensive income for the period		<u>-</u>	<u>-</u>
Total comprehensive income for the period		<u>\$ 33,595</u>	<u>\$ 6,229</u>
Profit attributable to:			
The Company		\$ 18,477	\$ 3,426
Non-controlling interests		<u>15,118</u>	<u>2,803</u>
		<u>\$ 33,595</u>	<u>\$ 6,229</u>

(Continued)

	For the Six Months Ended June 30	
	2024	2023
Total comprehensive income attributable to:		
The Company	\$ 18,477	\$ 3,426
Non-controlling interests	<u>15,118</u>	<u>2,803</u>
	<u>\$ 33,595</u>	<u>\$ 6,229</u>
Cash inflow (outflow) from:		
Operating activities	\$ 68,509	\$ 93,508
Investing activities	(38,898)	23,383
Financing activities	(34,192)	(283,033)
Effects of foreign currency exchange differences	<u>10,651</u>	<u>(12,761)</u>
Net cash inflow (outflow)	<u>\$ 6,070</u>	<u>\$ (178,903)</u> (Concluded)

13. INVESTMENTS ACCOUNTED FOR USING THE EQUITY METHOD

Investments in Associates

	June 30, 2024	December 31, 2023	June 30, 2023	
Associate that is not individually material				
Sawit Ecoshield Sdn. Bhd.	\$ 24,226	\$ 22,343	\$ 18,609	
EEMSB	<u>-</u>	<u>-</u>	<u>-</u>	
	<u>\$ 24,226</u>	<u>\$ 22,343</u>	<u>\$ 18,609</u>	
	For the Three Months Ended June 30		For the Six Months Ended June 30	
	2024	2023	2024	2023
The Group's share of:				
Profit for the period	<u>\$ 2,554</u>	<u>\$ 555</u>	<u>\$ 1,255</u>	<u>\$ 1,638</u>

The Group's investment in EEMSB was accounted for using the equity method. When EEMSB issued new shares in April 2023, the original shareholders did not further subscribe at their initial ownership proportion. After the transaction, the proportion of Group's ownership increased from 40% to 60%, and the Group is able to obtain control over EEMSB. Therefore, EEMSB has been one of the Group's components since April 2023. Refer to Notes 12 and 28 for the relevant disclosures.

Refer to Table 7 "Information on Investees" for the nature of activities, the principal places of business and the country of incorporation of the associates.

Investments accounted for using the equity method and the share of profit or loss and other comprehensive income of those investments were calculated based on unaudited financial statements. The management believes there is no material impact on the aforementioned unaudited financial statements.

14. PROPERTY, PLANT AND EQUIPMENT

Assets Used by the Group

	Land	Buildings	Machinery and Equipment	Transportation Equipment	Furniture, Fixture and Equipment	Leasehold Improvements	Other Equipment	Property under Construction	Total
Cost									
Balance at January 1, 2024	\$ 25,736	\$ 382,407	\$ 415,963	\$ 23,277	\$ 9,664	\$ 8,076	\$ 103,478	\$ 139,858	\$ 1,108,459
Additions	-	-	4,014	3,003	1,042	-	358	75,648	84,065
Disposals	-	-	(318)	(2,229)	-	-	-	-	(2,547)
Reclassification (Note)	-	4,573	1,265	-	-	-	-	(5,515)	323
Effects of foreign currency exchange differences	696	10,425	11,340	621	272	219	2,803	(1,575)	24,801
Balance at June 30, 2024	<u>\$ 26,432</u>	<u>\$ 397,405</u>	<u>\$ 432,264</u>	<u>\$ 24,672</u>	<u>\$ 10,978</u>	<u>\$ 8,295</u>	<u>\$ 106,639</u>	<u>\$ 208,416</u>	<u>\$ 1,215,101</u>
Accumulated depreciation									
Balance at January 1, 2024	\$ -	\$ 81,248	\$ 310,517	\$ 17,383	\$ 5,109	\$ 654	\$ 52,389	\$ -	\$ 467,300
Depreciation expense	-	3,963	10,148	1,187	553	190	4,045	-	20,086
Disposals	-	-	(262)	(2,229)	-	-	-	-	(2,491)
Effects of foreign currency exchange differences	-	2,271	8,580	427	145	22	1,493	-	12,938
Balance at June 30, 2024	<u>\$ -</u>	<u>\$ 87,482</u>	<u>\$ 328,983</u>	<u>\$ 16,768</u>	<u>\$ 5,807</u>	<u>\$ 866</u>	<u>\$ 57,927</u>	<u>\$ -</u>	<u>\$ 497,833</u>
Carrying amount at June 30, 2024	<u>\$ 26,432</u>	<u>\$ 309,923</u>	<u>\$ 103,281</u>	<u>\$ 7,904</u>	<u>\$ 5,171</u>	<u>\$ 7,429</u>	<u>\$ 48,712</u>	<u>\$ 208,416</u>	<u>\$ 717,268</u>
Carrying amount at December 31, 2023 and January 1, 2024	<u>\$ 25,736</u>	<u>\$ 301,159</u>	<u>\$ 105,446</u>	<u>\$ 5,894</u>	<u>\$ 4,555</u>	<u>\$ 7,422</u>	<u>\$ 51,089</u>	<u>\$ 139,858</u>	<u>\$ 641,159</u>
Cost									
Balance at January 1, 2023	\$ 26,784	\$ 385,438	\$ 403,775	\$ 22,758	\$ 8,163	\$ 637	\$ 94,757	\$ 33,456	\$ 975,768
Acquisition through business combinations (Note 28)	-	-	-	-	19	-	-	138	157
Additions	-	-	5,497	2,353	880	-	1,570	68,041	78,341
Disposals	-	-	(2,821)	(504)	-	-	(22)	-	(3,347)
Reclassification (Note)	-	-	27,601	-	-	4,975	2,107	(30,319)	4,364
Effects of foreign currency exchange differences	(1,179)	(16,971)	(18,594)	(987)	(371)	(162)	(4,267)	344	(42,187)
Balance at June 30, 2023	<u>\$ 25,605</u>	<u>\$ 368,467</u>	<u>\$ 415,458</u>	<u>\$ 23,620</u>	<u>\$ 8,691</u>	<u>\$ 5,450</u>	<u>\$ 94,145</u>	<u>\$ 71,660</u>	<u>\$ 1,013,096</u>
Accumulated depreciation									
Balance at January 1, 2023	\$ -	\$ 76,477	\$ 309,960	\$ 18,100	\$ 4,495	\$ 498	\$ 46,827	\$ -	\$ 456,357
Acquisition through business combinations (Note 28)	-	-	-	-	2	-	-	-	2
Depreciation expense	-	3,862	9,836	995	419	38	3,685	-	18,835
Disposals	-	-	(2,821)	(504)	-	-	(22)	-	(3,347)
Effects of foreign currency exchange differences	-	(3,472)	(13,836)	(751)	(205)	(23)	(2,159)	-	(20,446)
Balance at June 30, 2023	<u>\$ -</u>	<u>\$ 76,867</u>	<u>\$ 303,139</u>	<u>\$ 17,840</u>	<u>\$ 4,711</u>	<u>\$ 513</u>	<u>\$ 48,331</u>	<u>\$ -</u>	<u>\$ 451,401</u>
Carrying amount at June 30, 2023	<u>\$ 25,605</u>	<u>\$ 291,600</u>	<u>\$ 112,319</u>	<u>\$ 5,780</u>	<u>\$ 3,980</u>	<u>\$ 4,937</u>	<u>\$ 45,814</u>	<u>\$ 71,660</u>	<u>\$ 561,695</u>

Note: The reclassification was from prepayment for equipment.

The Group did not recognize or reverse impairment loss for the six months period ended June 30, 2024 and 2023.

The above items of property, plant and equipment used by the Group are depreciated on a straight-line basis over their estimated useful lives as follows:

Buildings

Main buildings

33-52 years

Others

50 years

Machinery and equipment

3-10 years

Transportation equipment

5 years

Furniture, fixture and equipment

3-10 years

Leasehold improvements

3-25 years

Other equipment

10 years

Property, plant and equipment used by the Group and pledged as collateral for borrowings are set out in Note 34.

15. LEASE ARRANGEMENTS

a. Right-of-use assets

	June 30, 2024		December 31, 2023		June 30, 2023
<u>Carrying amount</u>					
Land	\$ 144,424		\$ 142,700		\$ 145,903
Buildings	6,570		6,994		8,850
Transportation equipment	<u>3,992</u>		<u>4,468</u>		<u>5,036</u>
	<u>\$ 154,986</u>		<u>\$ 154,162</u>		<u>\$ 159,789</u>
	For the Three Months Ended June 30		For the Six Months Ended June 30		
	2024	2023	2024	2023	
Additions to right-of-use assets			<u>\$ 1,432</u>	<u>\$ 11,733</u>	
Depreciation charge for right-of-use assets					
Land	\$ 1,252	\$ 981	\$ 2,199	\$ 1,937	
Buildings	1,031	879	2,033	1,516	
Transportation equipment	<u>290</u>	<u>290</u>	<u>573</u>	<u>497</u>	
	<u>\$ 2,573</u>	<u>\$ 2,150</u>	<u>\$ 4,805</u>	<u>\$ 3,950</u>	

In addition to the additions and recognized depreciation charges listed above, the right of use assets of the Group was not significant increased, subletting and impaired for the six months period ended June 30, 2024 and 2023.

b. Lease liabilities

	June 30, 2024		December 31, 2023		June 30, 2023
<u>Carrying amount</u>					
Current	<u>\$ 5,398</u>		<u>\$ 4,760</u>		<u>\$ 4,985</u>
Non-current	<u>\$ 3,418</u>		<u>\$ 5,084</u>		<u>\$ 7,265</u>

Range of discount rates for lease liabilities was as follows:

	June 30, 2024		December 31, 2023		June 30, 2023
Buildings	3.10%-5.39%		3.10%-5.39%		3.10%-5.39%
Transportation equipment	2.14%-2.96%		2.14%-2.96%		2.14%-2.96%

c. Other lease information

	For the Three Months Ended June 30		For the Six Months Ended June 30	
	2024	2023	2024	2023
Expenses relating to short-term leases	\$ 2,433	\$ 1,430	\$ 4,016	\$ 2,582
Expenses relating to low-value asset leases	\$ 296	\$ 176	\$ 656	\$ 334
Total cash outflow for leases			\$ (7,542)	\$ (6,585)

Certain worker hostels and furniture, fixtures and equipment are qualified as short-term and low-value asset leases by the Group. The Group has elected to apply the recognition exemption and did not recognize relevant leases as right-of-use assets and the corresponding lease liability.

Right-of-use assets used by the Group and pledged as collaterals for borrowings are set out in Note 34.

16. GOODWILL

	For the Six Months Ended June 30	
	2024	2023
<u>Cost</u>		
Balance at January 1	\$ 5,891	\$ 5,342
Acquisition through business combinations (Note 28)	-	779
Effects of foreign currency exchange differences	159	(260)
Balance at June 30	\$ 6,050	\$ 5,861
<u>Accumulated impairment losses</u>		
Balance at January 1	\$ 4,783	\$ 4,978
Effects of foreign currency exchange differences	129	(219)
Balance at June 30	\$ 4,912	\$ 4,759
Carrying amounts at January 1	\$ 1,108	\$ 364
Carrying amounts at June 30	\$ 1,138	\$ 1,102

The Group acquired Arif Efektif Sdn. Bhd. and EEMSB and recognized goodwill in relation to investment costs exceeding the fair value of the identifiable assets and assumed liabilities on the acquisition date. The group did not recognize or reverse impairment loss for the six months ended June 30, 2024 and 2023.

17. OTHER INTANGIBLE ASSETS

	Computer Software	Special Technology	Total
<u>Cost</u>			
Balance at January 1, 2024	\$ 5,660	\$ 8,675	\$ 14,335
Additions	1,118	-	1,118
Reclassification (Note)	270	-	270
Effects of foreign currency exchange differences	<u>178</u>	<u>235</u>	<u>413</u>
Balance at June 30, 2024	<u>\$ 7,226</u>	<u>\$ 8,910</u>	<u>\$ 16,136</u>
<u>Accumulated amortization</u>			
Balance at January 1, 2024	\$ 4,829	\$ 434	\$ 5,263
Amortization expense	268	437	705
Effects of foreign currency exchange differences	<u>136</u>	<u>20</u>	<u>156</u>
Balance at June 30, 2024	<u>\$ 5,233</u>	<u>\$ 891</u>	<u>\$ 6,124</u>
Carrying amount at June 30, 2024	<u>\$ 1,993</u>	<u>\$ 8,019</u>	<u>\$ 10,012</u>
Carrying amount at December 31, 2023 and January 1, 2024	<u>\$ 831</u>	<u>\$ 8,241</u>	<u>\$ 9,072</u>
<u>Cost</u>			
Balance at January 1, 2023	\$ 5,204	\$ -	\$ 5,204
Additions	145	-	145
Reclassification (Note)	-	8,870	8,870
Effects of foreign currency exchange differences	<u>(233)</u>	<u>(239)</u>	<u>(472)</u>
Balance at June 30, 2023	<u>\$ 5,116</u>	<u>\$ 8,631</u>	<u>\$ 13,747</u>
<u>Accumulated amortization</u>			
Balance at January 1, 2023	\$ 4,725	\$ -	\$ 4,725
Amortization expense	175	-	175
Effects of foreign currency exchange differences	<u>(212)</u>	<u>-</u>	<u>(212)</u>
Balance at June 30, 2023	<u>\$ 4,688</u>	<u>\$ -</u>	<u>\$ 4,688</u>
Carrying amount at June 30, 2023	<u>\$ 428</u>	<u>\$ 8,631</u>	<u>\$ 9,059</u>

Note: The reclassification was from prepayments.

Other intangible assets are amortized on a straight-line basis over their estimated useful lives as follows:

Computer software	5 years
Special technology	10 years

18. OTHER ASSETS

	June 30, 2024	December 31, 2023	June 30, 2023
<u>Current</u>			
Prepayments			
Prepayments for purchase	\$ 24,259	\$ 16,810	\$ 8,022
Office supplies	18,189	20,588	24,817
Input tax	30,005	18,151	11,977
Others	<u>15,058</u>	<u>9,663</u>	<u>13,271</u>
	<u>\$ 87,511</u>	<u>\$ 65,212</u>	<u>\$ 58,087</u>
Other			
Refundable deposits	\$ 2,184	\$ 395	\$ 435
Right to recover a product (Note 24)	<u>-</u>	<u>-</u>	<u>277</u>
	<u>\$ 2,184</u>	<u>\$ 395</u>	<u>\$ 712</u>
<u>Non-current</u>			
Refundable deposits	\$ 7,676	\$ 8,788	\$ 9,698
Prepayment for equipment	<u>3,613</u>	<u>7,988</u>	<u>5,548</u>
	<u>\$ 11,289</u>	<u>\$ 16,776</u>	<u>\$ 15,246</u>

19. BORROWINGS

a. Short-term borrowings

	June 30, 2024	December 31, 2023	June 30, 2023
<u>Secured borrowings (Note 34)</u>			
Bank loans	<u>\$ 25,409</u>	<u>\$ -</u>	<u>\$ -</u>

The range of interest rates on bank loans is 6.34%-6.37% per annum as of June 30, 2024.

b. Long-term borrowings

	June 30, 2024	December 31, 2023	June 30, 2023
<u>Secured borrowings (Note 34)</u>			
Bank loans (1)	\$ 30,603	\$ 34,657	\$ 39,222
Less: Current portion	<u>(10,369)</u>	<u>(9,857)</u>	<u>(9,601)</u>
Long-term borrowings	<u>\$ 20,234</u>	<u>\$ 24,800</u>	<u>\$ 29,621</u>

The details of the long-term bank loans are as follows:

	Effective Rate	June 30, 2024	December 31, 2023	June 30, 2023
<u>Variable rate</u>				
AmIslamic Bank medium-term secured loan in a total amount of MYR7,500 thousand, from March 22, 2022 to May 1, 2027, repayable in monthly installments of principal and interest started from April 5, 2022.	4.50%	<u>\$ 30,603</u>	<u>\$ 34,657</u>	<u>\$ 39,222</u>

20. BONDS PAYABLE

	June 30, 2024	December 31, 2023	June 30, 2023
Unsecured domestic convertible bonds	\$ 500,000	\$ 500,000	\$ 500,000
Unamortized bond discount	<u>(1,004)</u>	<u>(1,411)</u>	<u>(1,822)</u>
	498,996	498,589	498,178
Less: Current portion	<u>(498,996)</u>	<u>(498,589)</u>	<u>-</u>
	<u>\$ -</u>	<u>\$ -</u>	<u>\$ 498,178</u>

On September 21, 2022, the Company issued the first three-year zero coupon unsecured domestic convertible bonds with a par value of \$100 thousand and an aggregate principal amount of \$500,000 thousand. The following items are primary clauses in the prospectus:

a. Term

The three-year period is starting from September 21, 2022 to September 21, 2025.

b. Date and method of payment of interest and principal

As the bonds bear 0% interest, no interest payment schedule or method has been set. Except for cases where the bonds are converted to the Company's ordinary shares, put options will be exercised by the bondholders, and the bonds will be redeemed prior to maturity, or where the Company repurchases the bonds from securities firms or cancelled them, the bonds will be paid at par in cash at maturity.

c. Conversion

The bondholder has the right during the conversion period, from December 22, 2022 (3 months after the issue date) to September 21, 2025 (the maturity date), to convert its bonds into ordinary shares, except for the period of suspension of transfer according to the law: (i) the period beginning on the 15th trading day prior to the book closure date for the distribution of shares or cash dividends, the subscription of new shares due to a capital increase; (ii) the period beginning on the date of a capital reduction until one day prior to the trading day on which the shares of the Company are reissued after such reduction; and (iii) the day of conversion (subscription) during the changes of the face value of stock until the day before the start of trading of the new shares issued through exchange.

The price used by the Company in determining the number of ordinary shares to be issued upon conversion was initially NT\$79 per share. The conversion price will be adjusted according to the formula stated in the prospectus, should there be any changes in the issuance of ordinary shares. Due to the distribution of cash dividends by the Company, the conversion price as of June 30, 2024 and December 31, 2023, was adjusted to NT\$75.7 per share. Effective from July 1, 2024, the conversion price is further adjusted to NT\$74.2 per share.

d. Redemption

From December 22, 2022 (3 months after the issue date) to August 12, 2025 (40 days prior to the maturity date), if the closing price of the Company's ordinary shares listed on the stock exchange exceeds 30% of the conversion price for 30 consecutive trading days, the Company can redeem all the bonds before the maturity date.

From December 22, 2022 (3 months after the issue date) to August 12, 2025 (40 days prior to the maturity date), if the balance of the outstanding convertible bonds is lower than 10% of the original principal amount, the Company can redeem all the bonds before the maturity date.

e. Put option of the bondholders

From September 21, 2024 onwards (2 years after the issue date), bondholders can request the Company to redeem the bonds in cash at 102.01% of the principal amount (the yield to put is 1%).

The Company announced on July 17, 2024, that bondholders may exercise their put option with the base date for the put option set as September 21, 2024.

Movements of the host liability instrument and the conversion option derivative instrument in June 30, 2024 and 2023 were as follows:

	Host Liability Instrument	Conversion Option Derivative Instrument
Balance at January 1, 2024	\$ 498,589	\$ 19,500
Interest expense	407	-
Gain on fair value	<u>-</u>	<u>(2,900)</u>
Balance at June 30, 2024	<u>\$ 498,996</u>	<u>\$ 16,600</u>
Balance at January 1, 2023	\$ 497,774	\$ 8,950
Interest expense	404	-
Loss on fair value	<u>-</u>	<u>3,650</u>
Balance at June 30, 2023	<u>\$ 498,178</u>	<u>\$ 12,600</u>

21. OTHER LIABILITIES

	June 30, 2024	December 31, 2023	June 30, 2023
<u>Current</u>			
Other payables			
Payable for salaries and bonuses (including compensation of employees and remuneration of directors)	\$ 21,173	\$ 31,084	\$ 21,697
Payable for pension fees	2,861	4,280	3,048
Payable for dividends	64,034	-	160,085
Payable for freight	18,262	16,117	18,759
Payable for purchasing equipment and construction	12,282	19,540	502
Payable for commission	6,933	5,320	2,773
Payable for maintenance	4,379	3,396	5,489
Payable for professional service fees	2,687	4,605	4,243
Payable for marketing expenses	2,368	1,806	2,155
Payable for utilities	2,125	1,507	1,534
Payable for royalties	2,046	1,206	1,872
Payable for taxes	492	1,965	1,215
Payable for welfare	107	98	139
Others	<u>9,804</u>	<u>4,870</u>	<u>5,654</u>
	<u>\$ 149,553</u>	<u>\$ 95,794</u>	<u>\$ 229,165</u>
Other liabilities			
Guarantee deposits received	\$ 398	\$ 346	\$ 344
Refund liabilities (Note 24)	-	-	706
Other current liabilities (Note 33)	<u>-</u>	<u>405</u>	<u>-</u>
	<u>\$ 398</u>	<u>\$ 751</u>	<u>\$ 1,050</u>

22. RETIREMENT BENEFIT PLANS

a. Defined contribution plan

The subsidiaries are required to contribute a specified percentage of payroll costs to the retirement benefit scheme to fund the benefits in accordance with local regulation. Except for the abovementioned, the Group does not have any other retirement or pension plans for employees.

b. Defined benefit plans

The subsidiary in Indonesia adopted a defined benefit plan and actuarial calculations are conducted in accordance with the local Labor Standards Act. For the three and six months ended June 30, 2024, the pension expenses of defined benefit plans were \$(101) thousand, and these were calculated based on the pension cost rate determined by the actuarial calculation on December 31, 2023.

23. EQUITY

a. Share capital

Ordinary shares

	June 30, 2024	December 31, 2023	June 30, 2023
Shares authorized (in thousands of shares)	<u>600,000</u>	<u>600,000</u>	<u>600,000</u>
Shares authorized	<u>\$ 6,000,000</u>	<u>\$ 6,000,000</u>	<u>\$ 6,000,000</u>
Shares issued and fully paid (in thousands of shares)	<u>64,034</u>	<u>64,034</u>	<u>64,034</u>
Shares issued	<u>\$ 640,340</u>	<u>\$ 640,340</u>	<u>\$ 640,340</u>

Fully paid ordinary shares, which have a par value of \$10, carry one vote per share and carry a right to dividends.

b. Capital surplus

	June 30, 2024	December 31, 2023	June 30, 2023
May be used to offset a deficit, distributed as cash dividends, or transferred to share capital*			
Issuance of ordinary shares	\$ 775,964	\$ 775,964	\$ 775,964
Exercise of employee share options	2,675	2,675	2,675
Forfeited employee share options	2,862	2,862	2,862
<u>May not be used for any purpose</u>			
Others	<u>337</u>	<u>337</u>	<u>337</u>
	<u>\$ 781,838</u>	<u>\$ 781,838</u>	<u>\$ 781,838</u>

* Such capital surplus may be used to offset a deficit; in addition, when the Company has no deficit, such capital surplus may be distributed as cash dividends or transferred to share capital (limited to a certain percentage of the Company's capital surplus and to once a year).

c. Retained earnings and dividends policy

Under the dividends policy as set forth in the Articles, where the Company made a profit every six months of the fiscal year, the profit shall be first utilized for paying taxes, offsetting losses of previous years, setting aside as legal reserve 10% of the remaining profit, setting aside or reversing a special reserve in accordance with the laws and regulations, and then any remaining profit together with any undistributed retained earnings shall be used by the Company's board of directors as the basis for proposing a distribution plan. If the distribution is in the form of shares, it shall be resolved in the shareholders' meeting; if the distribution is in the form of cash, resolution shall be made in the board of directors' meeting and a report of such distribution shall be submitted in the shareholders' meeting. For the policies on the distribution of compensation of employees and remuneration of directors, refer to compensation of employees and remuneration of directors in Note 25 (g).

The Company's Articles also stipulate that dividends may be distributed in shares or in cash. Cash dividends shall be no less than 50% of the total dividends distributed.

An appropriation of earnings to a legal reserve shall be made until the legal reserve equals the Company's paid-in capital. The legal reserve may be used to offset deficit. If the Company has no deficit and the legal reserve has exceeded 25% of the Company's paid-in capital, the excess may be transferred to capital or distributed in cash.

When a special reserve is appropriated for cumulative net debit balance reserves from a prior period, the sum of net profit for the current period and items other than net profit that are included directly in the unappropriated earnings for the current period is used if the prior unappropriated earnings are not sufficient.

The appropriations of earnings for 2023 and 2022 were as follows:

	Appropriation of Earnings	
	Year Ended December 31	
	2023	2022
Legal reserve	<u>\$ 13,735</u>	<u>\$ 36,686</u>
Special reserve	<u>\$ 89,854</u>	<u>\$ (105,763)</u>
Cash dividends	<u>\$ 64,034</u>	<u>\$ 160,085</u>
Cash dividends per share (NT\$)	<u>\$ 1.00</u>	<u>\$ 2.50</u>

The above appropriations for cash dividends were resolved by the Company's board of directors on March 14, 2024 and March 22, 2023; the other proposed appropriations for 2023 and 2022 were resolved by the shareholders in their meetings on June 21, 2024 and June 12, 2023, respectively.

On August 27, 2024 and August 25, 2023, the Company's board of directors resolved not to distribute appropriations of the semi-annual earnings in 2024 and 2023, respectively.

d. Special reserve

	For the Six Months Ended	
	June 30	
	2024	2023
Balance at January 1	\$ 422,189	\$ 527,952
Appropriations in respect (reversal) of		
Debits (reversal of the debit) to other equity items	<u>89,854</u>	<u>(105,763)</u>
Balance at June 30	<u>\$ 512,043</u>	<u>\$ 422,189</u>

According to the Articles, special reserve should be appropriated for the amount equal to the difference between the net debit balance reserve of other equity items and the balance of special reserve appropriated on the reporting date. Any special reserve appropriated may be reversed to the extent that the net debit balance reverses and is thereafter distributed.

e. Other equity items

1) Exchange differences on translation of the financial statements of foreign operations

	For the Six Months Ended June 30	
	2024	2023
Balance at January 1	\$ (512,043)	\$ (422,189)
Recognized for the period		
Exchange differences on translation to the presentation currency	59,962	(102,480)
Exchange differences on translation of the financial statements of foreign operations	(9,982)	8,980
Related income tax	<u>2,396</u>	<u>(2,155)</u>
Balance at June 30	<u>\$ (459,667)</u>	<u>\$ (517,844)</u>

2) Unrealized gain/(loss) on financial assets at FVTOCI

	For the Six Months Ended June 30, 2024
Balance at January 1	\$ -
Recognized for the period	
Unrealized gain - equity instruments	<u>195</u>
Balance at June 30	<u>\$ 195</u>

f. Non-controlling interests

	For the Six Months Ended June 30	
	2024	2023
Balance at January 1	\$ 559,851	\$ 496,276
Share in profit for the period	21,332	10,529
Other comprehensive income (loss) during the period		
Exchange differences on translation to the presentation currency	15,348	(22,129)
Exchange differences on translation of the financial statements of foreign operations	(1,405)	(3)
Cash dividends distribution by subsidiaries	(17,067)	(20,360)
Increase in non-controlling interest arising from acquisition of a new subsidiary (Note 28)	-	19,109
Change in proportions of ownership in subsidiaries (Note 29)	<u>-</u>	<u>1,079</u>
Balance at June 30	<u>\$ 578,059</u>	<u>\$ 484,501</u>

24. REVENUE

	For the Three Months Ended June 30		For the Six Months Ended June 30	
	2024	2023	2024	2023
Fertilizer revenue	\$ 436,546	\$ 754,521	\$ 870,994	\$ 1,498,711
Health supplement revenue	<u>41,845</u>	<u>31,957</u>	<u>130,942</u>	<u>65,736</u>
	<u>\$ 478,391</u>	<u>\$ 786,478</u>	<u>\$ 1,001,936</u>	<u>\$ 1,564,447</u>

a. Contract information

Revenue from the sale of goods

The Group's revenue mainly comes from the sale of bio-organic and bio-chemical compound fertilizers and health supplements. All goods are sold at agreed-upon prices.

Partial probiotic product sales contracts include the right of return. Considering past experience, the Group estimates the most likely amounts of returns and recognizes refund liabilities (other current liabilities) and the right to recover products (other current assets) accordingly.

b. Contract balances

	June 30, 2024	December 31, 2023	June 30, 2023	January 1, 2023
Trade receivables (including related parties)	<u>\$ 452,267</u>	<u>\$ 443,609</u>	<u>\$ 787,735</u>	<u>\$ 698,648</u>
Contract liabilities - current	<u>\$ 2,340</u>	<u>\$ 907</u>	<u>\$ 29,571</u>	<u>\$ 6,006</u>

c. Disaggregation of revenue

Refer to Note 39 for details of disaggregation of revenue.

25. NET PROFIT

a. Interest income

	For the Three Months Ended June 30		For the Six Months Ended June 30	
	2024	2023	2024	2023
Bank deposits	\$ 10,935	\$ 5,397	\$ 19,575	\$ 10,600
Financial assets at amortized cost	844	504	1,948	1,101
Loans to related party (Note 33)	<u>113</u>	<u>146</u>	<u>223</u>	<u>294</u>
	<u>\$ 11,892</u>	<u>\$ 6,047</u>	<u>\$ 21,746</u>	<u>\$ 11,995</u>

b. Other income

	For the Three Months Ended June 30		For the Six Months Ended June 30	
	2024	2023	2024	2023
Insurance compensation income	\$ -	\$ -	\$ 8,339	\$ -
Rental income	12	6	17	14
Others	<u>1,218</u>	<u>752</u>	<u>2,288</u>	<u>2,020</u>
	<u>\$ 1,230</u>	<u>\$ 758</u>	<u>\$ 10,644</u>	<u>\$ 2,034</u>

c. Other gains and losses

	For the Three Months Ended June 30		For the Six Months Ended June 30	
	2024	2023	2024	2023
Gain on disposal of property, plant and equipment	\$ 993	\$ 205	\$ 1,003	\$ 274
Net foreign exchange gains (h)	8,539	15,774	18,751	41,225
Fair values changes of financial assets and liabilities				
Financial assets mandatorily classified as at FVTPL	445	56	1,039	56
Financial liabilities held for trading	<u>(1,500)</u>	<u>9,850</u>	<u>2,900</u>	<u>(3,650)</u>
	<u>\$ 8,477</u>	<u>\$ 25,885</u>	<u>\$ 23,693</u>	<u>\$ 37,905</u>

d. Finance costs

	For the Three Months Ended June 30		For the Six Months Ended June 30	
	2024	2023	2024	2023
Interest on bank loans	\$ 795	\$ 632	\$ 1,234	\$ 1,222
Interest on lease liabilities	109	127	214	186
Interest on convertible bonds	<u>203</u>	<u>203</u>	<u>407</u>	<u>404</u>
	<u>\$ 1,107</u>	<u>\$ 962</u>	<u>\$ 1,855</u>	<u>\$ 1,812</u>

e. Depreciation and amortization

	For the Three Months Ended June 30		For the Six Months Ended June 30	
	2024	2023	2024	2023
An analysis of depreciation by function				
Operating costs	\$ 7,106	\$ 6,848	\$ 13,911	\$ 13,581
Operating expenses	<u>5,749</u>	<u>4,700</u>	<u>10,980</u>	<u>9,204</u>
	<u>\$ 12,855</u>	<u>\$ 11,548</u>	<u>\$ 24,891</u>	<u>\$ 22,785</u>

(Continued)

	For the Three Months Ended June 30		For the Six Months Ended June 30	
	2024	2023	2024	2023
An analysis of amortization by function				
Operating expenses	\$ <u>385</u>	\$ <u>57</u>	\$ <u>705</u>	\$ <u>175</u> (Concluded)

f. Employee benefits expense

	For the Three Months Ended June 30		For the Six Months Ended June 30	
	2024	2023	2024	2023
Post-employment benefits				
Defined contribution plan	\$ 3,495	\$ 3,120	\$ 6,870	\$ 6,251
Defined benefit plans	101	-	101	-
Other employee benefits	<u>50,720</u>	<u>54,223</u>	<u>104,663</u>	<u>105,440</u>
	\$ <u>54,316</u>	\$ <u>57,343</u>	\$ <u>111,634</u>	\$ <u>111,691</u>
An analysis of employee benefits expense by function				
Operating costs	\$ 17,166	\$ 20,942	\$ 34,220	\$ 41,225
Operating expenses	<u>37,150</u>	<u>36,401</u>	<u>77,414</u>	<u>70,466</u>
	\$ <u>54,316</u>	\$ <u>57,343</u>	\$ <u>111,634</u>	\$ <u>111,691</u>

g. Compensation of employees and remuneration of directors

According to the Articles, the Company accrues compensation of employees at rates of no less than 1% and no higher than 10% and remuneration of directors at rates of no higher than 10%, respectively, of net profit before income tax, compensation of employees, and remuneration of directors. The compensation of employees and the remuneration of directors for the three months ended June 30, 2024 and 2023 and for the six months ended June 30, 2024 and 2023 are as follows:

Accrual rate

	For the Six Months Ended June 30	
	2024	2023
Compensation of employees	3%	3%
Remuneration of directors	2%	2%

Amount

	For the Three Months Ended June 30		For the Six Months Ended June 30	
	2024	2023	2024	2023
Compensation of employees	\$ <u>163</u>	\$ <u>1,227</u>	\$ <u>1,151</u>	\$ <u>2,501</u>
Remuneration of directors	\$ <u>108</u>	\$ <u>818</u>	\$ <u>767</u>	\$ <u>1,667</u>

If there is a change in the amounts after the annual consolidated financial statements are authorized for issue, the differences are recorded as a change in the accounting estimate.

The appropriations of employees' compensation and remuneration of directors for 2023 and 2022 that were resolved by the board of directors on March 14, 2024 and March 22, 2023, respectively, are as shown below:

	For the Year Ended December 31			
	2023		2022	
	Cash	Shares	Cash	Shares
Compensation of employees	<u>\$ 4,394</u>	\$ -	<u>\$ 11,627</u>	\$ -
Remuneration of directors	<u>\$ 2,930</u>	-	<u>\$ 7,752</u>	-

There is no difference between the actual amounts of compensation of employees and remuneration of directors paid and the amounts recognized in the consolidated financial statements for the years ended December 31, 2023 and 2022.

Information on the compensation of employees and remuneration of directors resolved by the Company's board of directors is available at the Market Observation Post System website of the Taiwan Stock Exchange.

h. Gains and losses on foreign currency exchange

	For the Three Months Ended		For the Six Months Ended	
	June 30		June 30	
	2024	2023	2024	2023
Foreign exchange gains	\$ 18,148	\$ 17,742	\$ 52,500	\$ 107,299
Foreign exchange losses	<u>(9,609)</u>	<u>(1,968)</u>	<u>(33,749)</u>	<u>(66,074)</u>
	<u>\$ 8,539</u>	<u>\$ 15,774</u>	<u>\$ 18,751</u>	<u>\$ 41,225</u>

26. INCOME TAXES

a. Income tax recognized in profit or loss

Major components of income tax expense are as follow:

	For the Three Months Ended		For the Six Months Ended	
	June 30		June 30	
	2024	2023	2024	2023
Current tax				
In respect of the current period	\$ 16,117	\$ 2,150	\$ 33,732	\$ 22,459
Adjustments for prior year	<u>(146)</u>	<u>(773)</u>	<u>47</u>	<u>343</u>
	<u>15,971</u>	<u>1,377</u>	<u>33,779</u>	<u>22,802</u>
Deferred tax				
In respect of the current period	<u>(4,494)</u>	<u>4,467</u>	<u>(7,021)</u>	<u>4,051</u>
Income tax expense recognized in profit or loss	<u>\$ 11,477</u>	<u>\$ 5,844</u>	<u>\$ 26,758</u>	<u>\$ 26,853</u>

For the six months ended June 30, 2024 and 2023, the main source of income of the Group is the subsidiaries in Malaysia, whose tax rate is 24%, and the tax rate of the subsidiaries in Indonesia is 22%. Tax rates used by other entities operating in other jurisdictions are based on the tax laws in each jurisdiction.

b. Income tax recognized in other comprehensive income

	For the Three Months Ended June 30		For the Six Months Ended June 30	
	2024	2023	2024	2023
<u>Deferred tax</u>				
In respect of the current period				
Exchange differences on translation of the financial statements of foreign operations	<u>\$ (2,412)</u>	<u>\$ 1,793</u>	<u>\$ (2,396)</u>	<u>\$ 2,155</u>

c. Income tax assessments

As of June 30, 2024, the Group did not have any claim or litigation regarding tax assessment.

27. EARNINGS PER SHARE

	For the Three Months Ended June 30		For the Six Months Ended June 30	
	2024	2023	2024	2023
Basic earnings per share	<u>\$ 0.12</u>	<u>\$ 0.61</u>	<u>\$ 0.57</u>	<u>\$ 1.24</u>
Diluted earnings per share	<u>\$ 0.12</u>	<u>\$ 0.42</u>	<u>\$ 0.48</u>	<u>\$ 1.18</u>

The earnings and weighted average number of ordinary shares outstanding used in the computation of earnings per share were as follows:

Net Profit for the Period

	For the Three Months Ended June 30		For the Six Months Ended June 30	
	2024	2023	2024	2023
Profit for the period attributable to owners of the Company	<u>\$ 7,961</u>	<u>\$ 38,868</u>	<u>\$ 36,446</u>	<u>\$ 79,198</u>
Net income used in the computation of basic earnings per share	\$ 7,961	\$ 38,868	\$ 36,446	\$ 79,198
Effects of potentially dilutive ordinary shares				
After-tax interest and evaluation of convertible bonds	<u>—[*]</u>	<u>(9,647)</u>	<u>(2,493)</u>	<u>4,054</u>
Earnings used in the computation of diluted earnings per share	<u>\$ 7,961</u>	<u>\$ 29,221</u>	<u>\$ 33,953</u>	<u>\$ 83,252</u>

Weighted Average Number of Ordinary Shares Outstanding (In Thousand Shares)

	For the Three Months Ended June 30		For the Six Months Ended June 30	
	2024	2023	2024	2023
Weighted average number of ordinary shares used in the computation of basic earnings per share	64,034	64,034	64,034	64,034
Effects of potentially dilutive ordinary shares				
Compensation of employees	24	41	58	118
Convertible bonds	<u>-*</u>	<u>6,329</u>	<u>6,605</u>	<u>6,329</u>
Weighted average number of ordinary shares used in the computation of diluted earnings per share	<u>64,058</u>	<u>70,404</u>	<u>70,697</u>	<u>70,481</u>

* Convertible bonds are anti-dilutive, so they are excluded from the computation of diluted earnings per share.

The Group may settle compensation of employees in cash or shares; therefore the Group assumes that the entire amount of the compensation will be settled in shares, and the resulting potential shares will be included in the weighted average number of shares outstanding used in the computation of diluted earnings per share, as the effect is dilutive. Such dilutive effect of the potential shares is included in the computation of diluted earnings per share until the number of shares to be distributed to employees is resolved in the following year.

28. BUSINESS COMBINATIONS

In order to develop the health food business, the Group subscribed for the new shares issued by EEMSB and acquired an additional 20% ownership interest in EEMSB for \$17,233 thousand (equivalent to MYR2,500 thousand) in April 2023. The proportion of ownership interest in EEMSB increased from 40% to 60%, and the Group is able to obtain control over EEMSB.

a. Assets acquired and liabilities assumed at the date of acquisition

	EEMSB
Current assets	
Cash and cash equivalents	\$ 46,861
Prepayments	551
Non-current assets	
Plant and equipment	155
Other non-current assets	492
Current liabilities	
Trade and other payables	<u>(286)</u>
	<u>\$ 47,773</u>

b. Non-controlling interests

The non-controlling interest recognized at the date of acquisition was measured by reference to the share of the amount that the net identifiable assets of EEMSB had recognized.

c. Goodwill recognized on acquisitions

	EEMSB
Consideration transferred	\$ 17,223
Plus: Fair value of the interest held by the Group on the acquisition date	12,220
Non-controlling interest	19,109
Less: Fair value of identifiable net assets acquired	<u>(47,773)</u>
Goodwill recognized on acquisitions	<u>\$ 779</u>

The goodwill recognized in the acquisitions of EEMSB mainly represents the control premium included in the cost of the combinations. In addition, the consideration paid for the combinations effectively included amounts attributed to the benefits of expected synergies, revenue growth, future market development and the assembled workforces of EEMSB. These benefits are not recognized separately from goodwill because they do not meet the recognition criteria for identifiable intangible assets.

The total amount of acquired goodwill is not tax-deductible.

d. Net cash outflow (inflow) on the acquisition of subsidiaries

	EEMSB
Consideration paid in cash	\$ 17,223
Less: Cash and cash equivalent balances acquired	<u>(46,861)</u>
	<u>\$ (29,638)</u>

e. Impact of acquisitions on the results of the Group

The financial results of the acquirees since the acquisition dates, which are included in the consolidated statements of comprehensive income, were as follows:

	EEMSB
Operating revenue	<u>\$ 2,182</u>
Net loss for the period	<u>\$ (1,692)</u>

Had these business combinations been in effect at the beginning of the financial year, the Group's revenue would have been \$1,564,447 thousand, and the net profit would have been \$89,411 thousand for the six months ended June 30, 2023. This pro forma information is for illustrative purposes only and is not necessarily an indication of the revenue and results of operations of the Group that would have been achieved had the acquisition been completed on January 1, 2023, nor is it intended to be a projection of future results.

29. EQUITY TRANSACTIONS WITH NON-CONTROLLING INTERESTS

In February and March 2023, the Group subscribed for new shares issued by PTACB at a percentage different from its existing ownership proportion, which increased its continuing interest from 91% to 95%.

The above transaction was accounted for as an equity transaction since the Group did not lose control over this subsidiary.

	PTACB
Cash consideration paid	\$ (122,061)
The proportionate share of the carrying amount of the net assets of the subsidiary	<u>120,982</u>
Difference recognized from equity transactions	<u>\$ (1,079)</u>
<u>Line items adjusted for equity transactions</u>	
Unappropriated earnings	<u>\$ (1,079)</u>

30. CASH FLOWS INFORMATION

a. Non-cash transaction

For the six months ended June 30, 2024 and 2023, the Group entered into the following non-cash investing and financing activities which were not reflected in the consolidated statements of cash flows:

- 1) As of June 30, 2024, December 31, 2023 and June 30, 2023, the payable for purchasing equipment and constructors (recognized as other payables and other payables of related parties) were \$12,282 thousand, \$30,390 thousand and \$502 thousand, respectively.
- 2) As of June 30, 2024 and 2023, cash dividends resolved by the board of directors but not yet distributed were \$64,034 thousand and \$160,085 thousand, respectively. (Refer to Notes 21 and 23)

b. Changes in liabilities from financing activities

For the six months ended June 30, 2024

	Opening Balance	Cash Flows	Non-cash Changes				Closing Balance
			New Leases	Interest Expenses	Exchange Differences	Others	
Short-term borrowings	\$ -	\$ 25,572	\$ -	\$ -	\$ (163)	\$ -	\$ 25,409
Long-term borrowings	34,657	(4,902)	-	-	848	-	30,603
Guarantee deposits received	346	42	-	-	10	-	398
Lease liabilities	9,844	(2,656)	1,432	214	196	(214)	8,816
Bonds payable	498,589	-	-	407	-	-	498,996
Other payables to related parties	-	413	-	-	-	(199)	214
	<u>\$ 543,436</u>	<u>\$ 18,469</u>	<u>\$ 1,432</u>	<u>\$ 621</u>	<u>\$ 891</u>	<u>\$ (413)</u>	<u>\$ 564,436</u>

For the six months ended June 30, 2023

	Opening Balance	Cash Flows	Non-cash Changes				Closing Balance
			New Leases	Interest Expenses	Exchange Differences	Others	
Short-term borrowings	\$ 394,475	\$ (387,547)	\$ -	\$ -	\$ (6,928)	\$ -	\$ -
Long-term borrowings	45,906	(4,791)	-	-	(1,893)	-	39,222
Guarantee deposits received	68	287	-	-	(11)	-	344
Lease liabilities	4,309	(3,483)	11,733	186	(309)	(186)	12,250
Bonds payable	497,774	-	-	404	-	-	498,178
Other payables to related parties	-	3	-	-	-	-	3
	<u>\$ 942,532</u>	<u>\$ (395,531)</u>	<u>\$ 11,733</u>	<u>\$ 590</u>	<u>\$ (9,141)</u>	<u>\$ (186)</u>	<u>\$ 549,997</u>

31. CAPITAL MANAGEMENT

The Group manages its capital to ensure that entities in the Group will be able to continue as going concerns while maximizing the return to stakeholders through the optimization of the debt and equity balance. The Group's overall strategy remains unchanged.

The management of the Group periodically reviews its capital structure. As part of the review, the management considers the cost of capital, and the risks associated with each borrowing and the financial ratio required to determine the reasonable scale of capital structure of the Group. The Group balances its overall capital structure by distributing dividend, issuing new shares and obtaining loans.

32. FINANCIAL INSTRUMENTS

a. Fair value of financial instruments not measured at fair value

Except as detailed below, the Group's management believes that the carrying amount of financial assets and financial liabilities that are not measured at fair value approximates the fair value.

June 30, 2024

	Carrying Amount	Fair Value			Total
		Level 1	Level 2	Level 3	
<u>Financial liabilities</u>					
Financial liabilities at amortized cost					
Convertible bonds	<u>\$ 498,996</u>	<u>\$ -</u>	<u>\$ -</u>	<u>\$ 490,950</u>	<u>\$ 490,950</u>

December 31, 2023

	Carrying Amount	Fair Value			Total
		Level 1	Level 2	Level 3	
<u>Financial liabilities</u>					
Financial liabilities at amortized cost					
Convertible bonds	<u>\$ 498,589</u>	<u>\$ -</u>	<u>\$ -</u>	<u>\$ 487,050</u>	<u>\$ 487,050</u>

June 30, 2023

	Carrying Amount	Fair Value			Total
		Level 1	Level 2	Level 3	
<u>Financial liabilities</u>					
Financial liabilities at amortized cost					
Convertible bonds	\$ 498,178	\$ -	\$ -	\$ 484,050	\$ 484,050

For the measurement of fair value of the liability component of the convertible bond included in Level 3, the Group assumes that the bond will be redeemed at maturity and determines the risk discount rate with reference to the interest rate of borrowings of companies in the same industry, then extrapolates the per-hundred price.

b. Fair value of financial instruments measured at fair value on a recurring basis

1) Fair value hierarchy

June 30, 2024

	Level 1	Level 2	Level 3	Total
Financial assets at FVTPL				
Mutual funds	\$ 42,734	\$ -	\$ -	\$ 42,734
Financial assets at FVTOCI				
Investments in equity instruments - domestic unlisted shares	\$ -	\$ -	\$ 4,917	\$ 4,917
Financial liabilities at FVTPL				
Convertible bonds options	\$ -	\$ -	\$ 16,600	\$ 16,600

December 31, 2023

	Level 1	Level 2	Level 3	Total
Financial assets at FVTPL				
Derivative instruments	\$ -	\$ 149	\$ -	\$ 149
Mutual funds	40,922	-	-	40,922
	\$ 40,922	\$ 149	\$ -	\$ 41,071
Financial liabilities at FVTPL				
Convertible bonds options	\$ -	\$ -	\$ 19,500	\$ 19,500

June 30, 2023

	Level 1	Level 2	Level 3	Total
Financial assets at FVTPL				
Mutual funds	\$ 40,036	\$ -	\$ -	\$ 40,036
Financial liabilities at FVTPL				
Convertible bonds options	\$ -	\$ -	\$ 12,600	\$ 12,600

There were no transfers between Levels 1 and 2 for the six months ended June 30, 2024 and 2023.

2) Reconciliation of Level 3 fair value measurements of financial instruments

For the six months ended June 30, 2024

Financial Assets	At Fair Value Through Profit or Loss Structured Deposits	At Fair Value Through Other Comprehensive Income Equity Instruments
Balance at January 1	\$ -	\$ -
Additions	10,028	4,632
Disposal	(10,113)	-
Recognized in profit or loss (other gains and losses)	85	-
Recognized in other comprehensive income	-	195
Effects of foreign currency exchange differences	<u>-</u>	<u>90</u>
Balance at June 30	<u>\$ -</u>	<u>\$ 4,917</u>

Financial Liabilities	At Fair Value Through Profit or Loss Convertible Bonds Options
Balance at January 1	\$ 19,500
Recognized in profit or loss (loss on financial instruments at FVTPL) - unrealized	<u>(2,900)</u>
Balance at June 30	<u>\$ 16,600</u>

For the six months ended June 30, 2023

Financial Liabilities	At Fair Value Through Profit or Loss Convertible Bond Options
Balance at January 1	\$ 8,950
Recognized in profit or loss (loss on financial instruments at FVTPL) - unrealized	<u>3,650</u>
Balance at June 30	<u>\$ 12,600</u>

3) Valuation techniques and inputs applied for the Level 2 fair value measurement

Financial Instruments	Valuation Technique and Inputs
Derivatives - foreign exchange forward contracts	Fair value of foreign exchange forward contracts is measured on the basis of quotations provided by financing institutions.

4) Valuation techniques and inputs applied for the Level 3 fair value measurement

<u>Financial Instruments</u>	<u>Valuation Technique and Inputs</u>
Structured deposits	Discounted cash flow: Eliminating future cash flow based on the contractual rate of return.
Domestic unlisted shares	Market approach: Refers to the transaction prices of similar assets or comparable targets and uses the implied value multiples and relevant transaction information from those prices to assess fair value.
Derivatives - convertible bond options	Binary tree model: By considering factors including the duration of bonds, the share price and its volatility, exercise price, risk-free rate, risk discount rate and liquidity risk.

c. Categories of financial instruments

	June 30, 2024	December 31, 2023	June 30, 2023
<u>Financial assets</u>			
FVTPL			
Mandatorily classified as at FVTPL	\$ 42,734	\$ 41,071	\$ 40,036
Amortized cost (1)	2,068,144	2,079,154	2,172,255
FVTOCI			
Investments in equity instruments	4,917	-	-
<u>Financial liabilities</u>			
FVTPL			
Held for trading	16,600	19,500	12,600
Amortized cost (2)	718,988	733,437	647,547

1) The balances include financial assets at amortized cost, which comprise cash and cash equivalents, trade receivables, trade receivables from related parties, other receivables (excluding GST refund receivables), other receivables from related parties, financial assets at amortized cost and refundable deposits.

2) The balances include financial liabilities at amortized cost, which comprise short-term borrowings, trade payables, trade payables to related parties, other payables (excluding payable for salaries and bonuses, payable for pension fees, payable for taxes, payable for dividends, payable for welfare and insurance), other payables to related parties, bonds payable, current portion of long-term borrowings, long-term borrowings, and guarantee deposits received.

d. Financial risk management objectives and policies

The Group's major financial instruments include trade receivables, trade payables, bonds payable, lease liabilities and borrowings. The Group's corporate treasury function provides services to the business, coordinates access to domestic and international financial markets, monitors and manages the financial risks relating to the operations of the Group through internal risk reports which analyze exposures by degree and magnitude of risks. These risks include market risk (including foreign currency risk, interest rate risk and other price risk), credit risk and liquidity risk.

The Group seeks to minimize the effects of these risks by using derivative financial instruments to hedge risk exposures. The use of financial derivatives is governed by the Group's policies approved by the board of directors, which provided written principles on foreign currency risk, interest rate risk, credit risk, the use of financial derivatives and non-derivative financial instruments, and the investment of excess liquidity. Compliance with policies and exposure limits is reviewed by the internal auditors on a continuous basis. The Group did not enter into or trade financial instruments, including derivative financial instruments, for speculative purposes.

1) Market risk

The Group's activities exposed it primarily to the financial risks of changes in foreign currency risk, interest risk and other price risk. The Group entered into forward foreign exchange contracts to hedge the foreign currency risk arising from the importations denominated in United States dollar.

a) Foreign currency risk

The Group has foreign currency-denominated transactions, which expose the Group to foreign currency risk. Foreign currency risk is managed by the delegated team, which regularly reviews the positions of assets and liabilities affected by foreign currencies and utilizes the foreign exchange forward contracts to manage the exchange rate exposures.

The carrying amounts of the Group's foreign currency-denominated monetary assets and monetary liabilities (including those eliminated on consolidation) and of the derivatives exposed to foreign currency risk at the end of the reporting period are set out in Note 37.

Sensitivity analysis

The Group is mainly exposed to the fluctuations of United States dollars (USD) and New Taiwan dollars (NTD).

The following table details the Group's sensitivity to a 5% increase and decrease in the functional currency against the relevant foreign currencies.

The sensitivity rate used when reporting foreign currency risk internally to key management personnel and representing management's assessment of the reasonably possible change in foreign exchange rates is 5%. The sensitivity analysis included only outstanding foreign currency-denominated monetary items (e.g., trade receivables, trade payables and borrowing), and adjusted their translation at the end of the year for a 5% change in foreign currency rates. A positive number below indicates an increase in pre-tax profit and other equity associated with functional currency strengthening 5% against the relevant foreign currency. For a 5% weakening of functional currency against the relevant foreign currency, there would be an equal and opposite impact on pre-tax profit and other equity, and the balances below would be negative.

	USD Impact	
	For the Six Months Ended	
	June 30	
	2024	2023
Profit or loss (i)	\$ 10,265	\$ 21,255

	NTD Impact	
	For the Six Months Ended	
	June 30	
	2024	2023
Profit or loss (ii)	\$ (28,142)	\$ (32,907)

- i. The result was mainly attributable to the exposure of outstanding bank deposits, trade receivables, trade payables and borrowings in USD that were not hedged at the end of the period.
- ii. The result was mainly attributable to the exposure of outstanding bank deposits, bonds payable and dividends payable in NTD that were not hedged at the end of the period.

The Group's sensitivity to foreign currency decreased during the current period, mainly due to the decrease of bank deposits in USD and liabilities in NTD.

b) Interest rate risk

The Group is exposed to interest rate risk because entities in the Group borrow funds at both fixed and floating interest rates.

The carrying amounts of the Group's financial assets and financial liabilities with exposure to interest rates at the end of the reporting period were as follows:

	June 30, 2024	December 31, 2023	June 30, 2023
Fair value interest rate risk			
Financial assets	\$ 553,461	\$ 543,026	\$ 447,030
Financial liabilities	507,812	508,433	510,428
Cash flow interest rate risk			
Financial assets	720,306	808,966	722,172
Financial liabilities	56,012	34,657	39,222

Sensitivity analysis

The sensitivity analysis below was determined based on the Group's exposure to interest rates for both derivatives and non-derivative instruments at the end of the reporting period. For floating rate liabilities, the analysis was prepared assuming the amount of the liability outstanding at the end of the period was outstanding for the whole year. A 1% increase or decrease was used when reporting interest rate risk internally to key management personnel and represents management's assessment of the reasonably possible change in interest rates.

If interest rates had been 1% higher/lower and all other variables were held constant, the Group's pre-tax profit for the six months ended June 30, 2024 and 2023 would have increased/decreased by \$3,321 thousand and \$3,415 thousand, respectively, which was mainly a result of the change in interest rate on its floating-rate bank deposits and borrowings.

The Group's sensitivity to interest rates has not changed significantly during the current period.

c) Other price risk

The Group was exposed to price risk through its investments in money market fund instruments and investments in equity securities, which were classified as financial assets at FVTPL and financial assets at FVTOCI. The investments are held for strategic purposes. The Group manages this exposure by maintaining a portfolio of investments with lower risks.

Sensitivity analysis

The sensitivity analysis below was determined based on the exposure to money market funds and equity price risks at the end of the period.

If money market funds and equity prices had been 1% higher/lower, pre-tax profit for the six months ended June 30, 2024 and 2023 would have increased/decreased by \$427 thousand and \$400 thousand, respectively, as a result of the changes in fair value of financial assets at FVTPL, and pre-tax profit for the six months ended June 30, 2024 would have increased/decreased by \$49 thousand, as a result of the changes in fair value of financial assets at FVTOCI.

The Group's sensitivity to equity prices increased during the current period, mainly due to the increase of financial assets at FVTOCI.

2) Credit risk

Credit risk refers to the risk that a counterparty will default on its contractual obligations, resulting in financial loss to the Group. At the end of the period, the Group's maximum exposure to credit risk, which would cause a financial loss to the Group due to the failure of the counterparty to discharge its obligations and due to financial guarantees provided by the Group, could be equal to the carrying amount of the respective recognized financial assets as stated in the balance sheets.

The Group's concentration of credit risk was 24%, 31% and 28% of total trade receivables as of June 30, 2024, December 31, 2023 and June 30, 2023, respectively, and was attributable to the three largest customers of the Group.

In order to minimize credit risk, the management of the Group delegated a team responsible for determining credit limits, credit approvals and other monitoring procedures to ensure that follow-up action is taken to recover overdue receivables.

3) Liquidity risk

The Group manages liquidity risk by monitoring and maintaining a level of cash and cash equivalents deemed adequate to finance the Group's operations and mitigate the effects of fluctuations in cash flows. In addition, management monitors the utilization of bank borrowings and ensures compliance with loan covenants.

The Group relies on bank borrowings as a significant source of liquidity. As of June 30, 2024, December 31, 2023 and June 30, 2023, the Group had available unutilized short-term bank loan facilities set out in (c) below.

a) Liquidity and interest rate risk tables for non-derivative financial liabilities

The following tables detail the Group's remaining contractual maturity for its non-derivative financial liabilities with agreed repayment periods. The tables have been drawn up based on the undiscounted cash flows of financial liabilities from the earliest date on which the Group can be required to pay. The tables included both interest and principal cash flows.

Specifically, bank loans with a repayment on demand clause were included in the earliest time band regardless of the probability of the banks choosing to exercise their rights. The maturity dates for other non-derivative financial liabilities were based on the agreed upon repayment dates.

To the extent that interest flows are at floating rates, the undiscounted amount was derived from the interest rate curve at the end of the period.

June 30, 2024

	On Demand or Less than 1 Month	1-3 Months	3 Months to 1 Year	1-5 Years	5+ Years
<u>Non-derivative financial liabilities</u>					
Non-interest bearing	\$ 122,342	\$ 105,207	\$ 465	\$ -	\$ -
Lease liabilities	488	975	4,256	3,516	-
Floating interest rate liabilities	26,391	1,921	8,640	21,119	-
Fixed interest rate liabilities	-	<u>500,000</u>	-	-	-
	<u>\$ 149,221</u>	<u>\$ 608,103</u>	<u>\$ 13,361</u>	<u>\$ 24,635</u>	<u>\$ -</u>

Additional information on the maturity analysis for lease liabilities:

	Less than 1 Year	1-5 Years	5-10 Years	10-15 Years	15-20 Years	20+ Years
Lease liabilities	<u>\$ 5,719</u>	<u>\$ 3,516</u>	<u>\$ -</u>	<u>\$ -</u>	<u>\$ -</u>	<u>\$ -</u>

December 31, 2023

	On Demand or Less than 1 Month	1-3 Months	3 Months to 1 Year	1-5 Years	5+ Years
<u>Non-derivative financial liabilities</u>					
Non-interest bearing	\$ 164,587	\$ 35,014	\$ 590	\$ -	\$ -
Lease liabilities	477	893	3,729	5,415	-
Floating interest rate liabilities	933	1,868	8,413	26,170	-
Fixed interest rate liabilities	-	-	<u>500,000</u>	-	-
	<u>\$ 165,997</u>	<u>\$ 37,775</u>	<u>\$ 512,732</u>	<u>\$ 31,585</u>	<u>\$ -</u>

Additional information on the maturity analysis for lease liabilities:

	Less than 1 Year	1-5 Years	5-10 Years	10-15 Years	15-20 Years	20+ Years
Lease liabilities	<u>\$ 5,099</u>	<u>\$ 5,415</u>	<u>\$ -</u>	<u>\$ -</u>	<u>\$ -</u>	<u>\$ -</u>

June 30, 2023

	On Demand or Less than 1 Month	1-3 Months	3 Months to 1 Year	1-5 Years	5+ Years
<u>Non-derivative financial liabilities</u>					
Non-interest bearing	\$ 84,104	\$ 185,557	\$ 571	\$ -	\$ -
Lease liabilities	473	945	4,015	7,542	-
Floating interest rate liabilities	930	1,860	8,370	31,605	-
Fixed interest rate liabilities	<u>-</u>	<u>-</u>	<u>-</u>	<u>500,000</u>	<u>-</u>
	<u>\$ 85,507</u>	<u>\$ 188,362</u>	<u>\$ 12,956</u>	<u>\$ 539,147</u>	<u>\$ -</u>

Additional information on the maturity analysis for lease liabilities:

	Less than 1 Year	1-5 Years	5-10 Years	10-15 Years	15-20 Years	20+ Years
Lease liabilities	<u>\$ 5,433</u>	<u>\$ 7,542</u>	<u>\$ -</u>	<u>\$ -</u>	<u>\$ -</u>	<u>\$ -</u>

The amount included the above floating interest rate instruments for both non-derivative financial assets and liabilities were subject to change if changes in floating interest rates differ from those estimates of interest rates determined at the end of the period.

b) Liquidity risk tables for derivative financial liabilities

The following table detailed the Group's liquidity analysis for its derivative financial instruments. The table is based on the undiscounted contractual net cash inflows and outflows on derivative instruments that settle on a net basis, and the undiscounted gross inflows and outflows on those derivatives that require gross settlement. When the amount payable or receivable is not fixed, the amount disclosed was determined by reference to the projected interest rates as illustrated by the yield curves at the end of the period.

December 31, 2023

	On Demand or Less than 1 Month	1-3 Months	3 Months to 1 Year	1-5 Years	5+ Years
<u>Net settled</u>					
Foreign exchange forward contracts	<u>\$ 149</u>	<u>\$ -</u>	<u>\$ -</u>	<u>\$ -</u>	<u>\$ -</u>

c) Financing facilities

	June 30, 2024	December 31, 2023	June 30, 2023
Secured bank loan facilities:			
Amount used	\$ 76,122	\$ 73,592	\$ 68,171
Amount unused	<u>1,163,901</u>	<u>1,123,593</u>	<u>1,161,653</u>
	<u>\$ 1,240,023</u>	<u>\$ 1,197,185</u>	<u>\$ 1,229,824</u>
Unsecured bank loan facilities:			
Amount used	\$ -	\$ -	\$ -
Amount unused	<u>66,334</u>	<u>62,957</u>	<u>47,627</u>
	<u>\$ 66,334</u>	<u>\$ 62,957</u>	<u>\$ 47,627</u>

33. TRANSACTIONS WITH RELATED PARTIES

Balances and transactions between the Company and its subsidiaries, which are related parties of the Company, have been eliminated on consolidation and are not disclosed in this note. Details of transactions between the Group and other related parties are disclosed as follows.

a. Related party names and categories

<u>Related Names</u>	<u>Related Party Categories</u>
Sabah Softwoods Berhad	Related party in substance
Sawit Kinabalu Seeds Sdn. Bhd.	Related party in substance
Borneo Samudera Sdn. Bhd.	Related party in substance
Bongalio Development Sdn. Bhd.	Related party in substance
Kalabakan Plantation Sdn. Bhd.	Related party in substance
Oscar Kinabalu Sdn. Bhd.	Related party in substance
Bagahak Plantation Sdn. Bhd.	Related party in substance
Saplantco Sdn. Bhd.	Related party in substance
Sawit Ecoshield Sdn. Bhd.	Associate
Eastern Eckare Malaysia Sdn. Bhd.	Associate before April 2023. As the Group's component since April 2023
Grape King Bio Ltd.	Related party in substance
Tan Chek Yen	Related party in substance
Peng Shih Hao	Key management personnel

b. Operating revenue

Line Item	Related Party Category/Name	For the Three Months Ended June 30		For the Six Months Ended June 30	
		2024	2023	2024	2023
Sales	Related parties in substance				
	Sabah Softwoods Berhad	\$ 76,976	\$ 13,531	\$ 169,765	\$ 155,603
	Others	92	40,366	92	55,812
	Associate	<u>10,820</u>	<u>10,279</u>	<u>16,653</u>	<u>20,147</u>
		<u>\$ 87,888</u>	<u>\$ 64,176</u>	<u>\$ 186,510</u>	<u>\$ 231,562</u>

The selling price for related parties is calculated with reference to the applicable market price. The credit terms for the related parties are comparable to those for unrelated parties.

c. Purchase of goods

Related Party Category/Name	For the Three Months Ended June 30		For the Six Months Ended June 30	
	2024	2023	2024	2023
Related parties in substance	<u>\$ 22,328</u>	<u>\$ 5,372</u>	<u>\$ 30,329</u>	<u>\$ 6,314</u>

Purchases of goods for related parties are calculated with reference to general market conditions. The payment term for the related parties are comparable to those of unrelated parties.

d. Receivables from related parties (excluding loans to related parties)

Line Item	Related Party Category/Name	June 30, 2024	December 31, 2023	June 30, 2023
		Trade receivables	Related parties in substance	\$ 40,449
	Associate	<u>8,468</u>	<u>4,541</u>	<u>4,384</u>
		48,917	37,813	34,943
Less: Allowance for impairment loss		<u>(426)</u>	<u>(218)</u>	<u>(24)</u>
		<u>\$ 48,491</u>	<u>\$ 37,595</u>	<u>\$ 34,919</u>
Other receivables	Associate	\$ 232	\$ -	\$ 286
	Related parties in substance	<u>7</u>	<u>-</u>	<u>-</u>
		<u>\$ 239</u>	<u>\$ -</u>	<u>\$ 286</u>

The outstanding receivables from related parties are unsecured.

The Group measures the loss allowance for trade receivables from related parties at an amount equal to lifetime ECLs. The expected credit losses on trade receivables from related parties are estimated using a provision matrix prepared by reference to the past default experience of the debtor and the debtor's current financial position. The following table details the loss allowance of trade receivables from related parties based on the Group's provision matrix.

Trade receivables from related parties

June 30, 2024

	Not Past Due	1 to 90 Days Past Due	91 to 180 Days Past Due	181 to 270 Days Past Due	Over 270 Days Past Due	Total
Expected credit loss rate	0.24%	1.99%	-	35.58%	100%	
Gross carrying amount	\$ 48,141	\$ 43	\$ -	\$ 657	\$ 76	\$ 48,917
Loss allowance (Lifetime ECLs)	<u>(115)</u>	<u>(1)</u>	<u>-</u>	<u>(234)</u>	<u>(76)</u>	<u>(426)</u>
Amortized cost	<u>\$ 48,026</u>	<u>\$ 42</u>	<u>\$ -</u>	<u>\$ 423</u>	<u>\$ -</u>	<u>\$ 48,491</u>

December 31, 2023

	Not Past Due	1 to 90 Days Past Due	91 to 180 Days Past Due	181 to 270 Days Past Due	Over 270 Days Past Due	Total
Expected credit loss rate	0.06%	0.64%	3.55%	25.64%	100%	
Gross carrying amount	\$ 35,636	\$ 1,416	\$ 535	\$ 78	\$ 148	\$ 37,813
Loss allowance (Lifetime ECLs)	<u>(22)</u>	<u>(9)</u>	<u>(19)</u>	<u>(20)</u>	<u>(148)</u>	<u>(218)</u>
Amortized cost	<u>\$ 35,614</u>	<u>\$ 1,407</u>	<u>\$ 516</u>	<u>\$ 58</u>	<u>\$ -</u>	<u>\$ 37,595</u>

June 30, 2023

	Not Past Due	1 to 90 Days Past Due	91 to 180 Days Past Due	181 to 270 Days Past Due	Over 270 Days Past Due	Total
Expected credit loss rate	0.02%	0.18%	9.02%	-	-	
Gross carrying amount	\$ 30,925	\$ 3,156	\$ 862	\$ -	\$ -	\$ 34,943
Loss allowance (Lifetime ECLs)	<u>(7)</u>	<u>(6)</u>	<u>(11)</u>	<u>-</u>	<u>-</u>	<u>(24)</u>
Amortized cost	<u>\$ 30,918</u>	<u>\$ 3,150</u>	<u>\$ 851</u>	<u>\$ -</u>	<u>\$ -</u>	<u>\$ 34,919</u>

The movements of the loss allowance of trade receivables from related parties were as follows:

	For the Six Months Ended June 30	
	2024	2023
Balance at January 1	\$ 218	\$ 12
Add: Net provision of loss allowance	199	12
Foreign exchange translation differences	<u>9</u>	<u>-</u>
Balance at June 30	<u>\$ 426</u>	<u>\$ 24</u>

e. Payables to related parties

Line Item	Related Party Category/Name	June 30, 2024	December 31, 2023	June 30, 2023
Trade payables	Related parties in substance	<u>\$ 22,874</u>	<u>\$ 22,429</u>	<u>\$ 5,407</u>
Other payables	Related parties in substance			
	Tan Chek Yen	\$ -	\$ 10,850	\$ -
	Other	<u>214</u>	<u>12</u>	<u>3</u>
		<u>\$ 214</u>	<u>\$ 10,862</u>	<u>\$ 3</u>

The outstanding payables to related parties are unsecured.

f. Lease arrangements - Group is lessee

Related Party Category/Name	For the Three Months Ended June 30		For the Six Months Ended June 30	
	2024	2023	2024	2023
<u>Lease expense</u>				
Related parties in substance	<u>\$ 123</u>	<u>\$ 71</u>	<u>\$ 243</u>	<u>\$ 144</u>

The Group leased an employees' dormitory from related parties in substance. The lease agreement was negotiated by both parties, and the rental was paid monthly.

g. Loans to related parties

Related Party Category/Name	June 30, 2024	December 31, 2023	June 30, 2023
Associate			
Sawit Ecoshield Sdn. Bhd.	<u>\$ 6,879</u>	<u>\$ 6,698</u>	<u>\$ 10,662</u>

Interest income

Related Party Category/Name	For the Three Months Ended June 30		For the Six Months Ended June 30	
	2024	2023	2024	2023
Associate				
Sawit Ecoshield Sdn. Bhd.	<u>\$ 113</u>	<u>\$ 146</u>	<u>\$ 223</u>	<u>\$ 294</u>

The Group provided its associate with unsecured short-term loans at rates comparable to market interest rates. These loans are expected to be collected within one year and assessed that there were no expected credit losses.

h. Other transactions with related parties

Line Item	Related Party Category/Name	June 30, 2024	December 31, 2023	June 30, 2023
Receipts in advance (recognized as other current liabilities)	Related party in substance Grape King Bio Ltd.	\$ <u> -</u>	\$ <u> 405</u>	\$ <u> -</u>

i. Remuneration of key management personnel

	For the Three Months Ended June 30		For the Six Months Ended June 30	
	2024	2023	2024	2023
Short-term employee benefits	\$ <u> 5,876</u>	\$ <u> 9,373</u>	\$ <u>16,535</u>	\$ <u>25,044</u>

The remuneration of directors and key executives, as determined by the remuneration committee, is based on the performance of individuals and market trends.

34. ASSETS PLEDGED AS COLLATERAL OR FOR SECURITY

The following assets were provided as collateral for bank borrowings and credit card guarantees:

	June 30, 2024	December 31, 2023	June 30, 2023
Financial assets at amortized cost - current	\$ 126,751	\$ 86,030	\$ 84,292
Buildings, net	297,851	289,283	291,600
Land	26,432	25,736	25,605
Right-of-use assets	<u>101,531</u>	<u>99,888</u>	<u>100,408</u>
	<u>\$ 552,565</u>	<u>\$ 500,937</u>	<u>\$ 501,905</u>

35. SIGNIFICANT CONTINGENT LIABILITIES AND UNRECOGNIZED COMMITMENTS

In addition to those disclosed in other notes, significant contingencies and unrecognized commitments of the Group as of June 30, 2024, December 31, 2023 and June 30, 2023 were as follows:

Unrecognized commitments were as follows:

	June 30, 2024	December 31, 2023	June 30, 2023
Acquisition of property, plant and equipment	<u>\$ 20,558</u>	<u>\$ 73,892</u>	<u>\$ 166,616</u>

36. SIGNIFICANT EVENTS AFTER THE REPORTING PERIOD

In July 2024, Cosmos Nutriscience Sdn. Bhd. (CNSB), the subsidiary of ACI, increased its capital by MYR1,700 thousand by cash. ACI and its non-controlling shareholder subscribed for MYR1,200 thousand and MYR500 thousand. ACI decreased its shareholding from 92% to 80% as a result of ACI not increasing its capital in proportion to its shareholding; however, it does not affect ACI's control over CNSB. As of the date of issuance of this consolidated financial statement, CNSB has completed the change in registration.

37. SIGNIFICANT ASSETS AND LIABILITIES DENOMINATED IN FOREIGN CURRENCIES

The Group's significant financial assets and liabilities denominated in foreign currencies aggregated by the foreign currencies other than functional currencies of the entities in the Group and the related exchange rates between foreign currencies and respective functional currencies were as follows:

June 30, 2024

	Foreign Currency	Exchange Rate	Carrying Amount
<u>Financial assets</u>			
Monetary items			
USD	\$ 11,900	4.8217 (USD:MYR)	\$ 394,665
USD	338	16,742 (USD:IDR)	11,218
NTD	184	0.1454 (NTD:MYR)	184

Financial liabilities

Monetary items			
USD	2,131	4.8217 (USD:MYR)	70,680
USD	3,917	16,742 (USD:IDR)	129,899
NTD	563,031	0.1454 (NTD:MYR)	563,031

December 31, 2023

	Foreign Currency	Exchange Rate	Carrying Amount
<u>Financial assets</u>			
Monetary items			
USD	\$ 12,151	4.7000 (USD:MYR)	\$ 348,723
USD	1,783	15,772 (USD:IDR)	55,193
NTD	495	0.1493 (NTD:MYR)	495

Financial liabilities

Monetary items			
USD	2,939	4.7000 (USD:MYR)	93,153
USD	2,376	15,772 (USD:IDR)	73,571
NTD	498,589	0.1493 (NTD:MYR)	498,589

June 30, 2023

	Foreign Currency	Exchange Rate	Carrying Amount
<u>Financial assets</u>			
Monetary items			
USD	\$ 15,550	4.7650 (USD:MYR)	\$ 493,632
USD	3,733	15,272 (USD:IDR)	118,490
NTD	119	0.1501 (NTD:MYR)	119
<u>Financial liabilities</u>			
Monetary items			
USD	1,112	4.7650 (USD:MYR)	35,370
USD	4,776	15,272 (USD:IDR)	151,651
NTD	658,263	0.1501 (NTD:MYR)	658,263

The significant realized and unrealized foreign exchange gains (losses) were as follows:

For the Three Months Ended June 30				
2024			2023	
Foreign Currency	Exchange Rate	Net Foreign Exchange Gains (Losses)	Exchange Rate	Net Foreign Exchange Gains (Losses)
USD	4.7290 (USD:MYR)	<u>\$ 5,318</u>	4.5306 (USD:MYR)	<u>\$ 16,199</u>
USD	16,146 (USD:IDR)	<u>\$ (5,767)</u>	14,858 (USD:IDR)	<u>\$ 12,978</u>
NTD	0.1462 (NTD:MYR)	<u>\$ 9,056</u>	0.1475 (NTD:MYR)	<u>\$ (12,347)</u>

For the Six Months Ended June 30				
2024			2023	
Foreign Currency	Exchange Rate	Net Foreign Exchange Gains (Losses)	Exchange Rate	Net Foreign Exchange Gains (Losses)
USD	4.7239 (USD:MYR)	<u>\$ 17,245</u>	4.4596 (USD:MYR)	<u>\$ 27,071</u>
USD	15,905 (USD:IDR)	<u>\$ (9,159)</u>	15,015 (USD:IDR)	<u>\$ 31,091</u>
NTD	0.1481 (NTD:MYR)	<u>\$ 12,099</u>	0.1460 (NTD:MYR)	<u>\$ (16,213)</u>

38. SEPARATELY DISCLOSED ITEMS

a. Information on significant transactions:

- 1) Financing provided to others (Table 1)
- 2) Endorsements/guarantees provided (Table 2)
- 3) Marketable securities held (excluding investments in subsidiaries, associates and joint ventures) (Table 3)
- 4) Marketable securities acquired or disposed of at costs or prices of at least NT\$300 million or 20% of the paid-in capital (None)

- 5) Acquisition of individual real estate at costs of at least NT\$300 million or 20% of the paid-in capital (None)
 - 6) Disposal of individual real estate at prices of at least NT\$300 million or 20% of the paid-in capital (None)
 - 7) Total purchases from or sales to related parties amounting to at least NT\$100 million or 20% of the paid-in capital (Table 4)
 - 8) Receivables from related parties amounting to at least NT\$100 million or 20% of the paid-in capital (Table 5)
 - 9) Trading in derivative instruments (Note 7)
 - 10) Intercompany relationships and significant intercompany transactions (Table 6)
- b. Information on investees (Table 7)
 - c. Information on investments in mainland China (None)
 - d. Information of major shareholders: List all shareholders with ownership of 5% or greater showing the name of the shareholder, the number of shares owned, and percentage of ownership of each shareholder (Table 8)

39. SEGMENT INFORMATION

Information reported to the chief operating decision maker for the purpose of resource allocation and assessment of segment performance focuses on the types of goods or services delivered or provided. Specifically, the Group's reportable segments were All Cosmos Industries Sdn. Bhd. (ACI), Sabah Softwoods Hybrid Fertiliser Sdn. Bhd. (SSHF) and others.

The details of the Group's reportable segments were as follows:

a. Segment revenues and results

The following was an analysis of the Group's revenue and results from continuing operations by reportable segments.

	<u>Segment Revenue</u>		<u>Segment Income</u>	
	<u>For the Six Months Ended</u>		<u>For the Six Months Ended</u>	
	<u>June 30</u>		<u>June 30</u>	
	<u>2024</u>	<u>2023</u>	<u>2024</u>	<u>2023</u>
ACI	\$ 458,916	\$ 875,311	\$ (33,051)	\$ 22,254
SSHF	288,255	429,664	33,784	12,765
Others	<u>254,765</u>	<u>259,472</u>	<u>37,693</u>	<u>42,641</u>
	<u>\$ 1,001,936</u>	<u>\$ 1,564,447</u>	38,426	77,660

(Continued)

	<u>Segment Revenue</u>		<u>Segment Income</u>	
	<u>For the Six Months Ended</u>		<u>For the Six Months Ended</u>	
	<u>June 30</u>		<u>June 30</u>	
	2024	2023	2024	2023
Interest income			\$ 21,746	\$ 11,995
Other income			10,644	2,034
Other gains and losses			23,693	37,905
Finance costs			(1,855)	(1,812)
Share of profit or loss of associates			1,255	1,638
General administration costs and remuneration of directors			<u>(9,373)</u>	<u>(12,840)</u>
Profit before tax			<u>\$ 84,536</u>	<u>\$ 116,580</u>
				(Concluded)

Segment revenue reported above represents revenue generated from external customers. The inter-segment sales for the six months ended June 30, 2024 and 2023 have both been eliminated.

Segment profit represents the profit before tax earned by each segment without allocation of general administration costs and remuneration of directors, share of profit or loss of associates, interest income, other income, other gains and losses, finance costs and income tax expense. This was the measure reported to the chief operating decision maker for the purpose of resource allocation and assessment of segment performance.

b. Segment total assets and liabilities

Segment total assets and liabilities are not provided to the chief operating decision maker and thus not required to be disclosed.

ALL COSMOS BIO-TECH HOLDING CORPORATION AND SUBSIDIARIES

FINANCING PROVIDED TO OTHERS
FOR THE SIX MONTHS ENDED JUNE 30, 2024
(In Thousands of New Taiwan Dollars, Unless Stated Otherwise)

No.	Lender	Borrower	Financial Statement Account	Related Party	Highest Balance for the Period (Note 2)	Ending Balance (Note 2)	Actual Amount Borrowed (Note 2)	Interest Rate %	Nature of Financing	Business Transaction Amount	Reasons for Short-term Financing	Allowance for Impairment Loss	Collateral		Financing Limit for Each Borrower	Aggregate Financing Limit
													Item	Value		
0	The Company	PT All Cosmos Biotek	Other receivables from related parties	Yes	\$ 55,369	\$ 55,369	\$ 16,583 (Note 3)	6.70	Short-term financing	\$ -	Operating capital	\$ -	-	\$ -	\$ 455,865	\$ 911,730
1	All Cosmos Industries Sdn. Bhd.	Cosmos Nutriscience Sdn. Bhd.	Other receivables from related parties	Yes	2,751	2,751	2,751 (Note 3)	4.08	Short-term financing	-	Operating capital	-	-	-	501,415	668,554
2	Sabah Softwoods Hybrid Fertiliser Sdn. Bhd.	Sawit Ecoshield Sdn. Bhd.	Other receivables from related parties	Yes	6,879	6,879	6,879	6.67	Short-term financing	-	Operating capital	-	-	-	259,239	345,652

Note 1: a The total amount of loans made by the Company to others with short-term financing needs shall not exceed 40% of the net asset value of the Company in its latest financial statements; the financing limit for each individual borrower is 20% of the Company's net asset value in its latest financial statements.

b The total amount of loans made from the subsidiaries to others with short-term financing needs shall not exceed 40% of the net asset value of the subsidiary in its latest financial statements; the financing limit for each individual borrower is 30% of the subsidiary's net asset value in its latest financial statements.

Note 2: The highest balance for the current period, the ending balance and the actual borrowing amount were translated at the exchange rate at the end of the reporting period.

Note 3: The transactions were eliminated in the consolidated financial statements.

ALL COSMOS BIO-TECH HOLDING CORPORATION AND SUBSIDIARIES

ENDORSEMENTS/GUARANTEES PROVIDED
FOR THE SIX MONTHS ENDED JUNE 30, 2024

(In Thousands of New Taiwan Dollars, Unless Stated Otherwise)

No.	Endorser/ Guarantor	Endorsee/Guarantee		Limit on Endorsement/ Guarantee Given on Behalf of Each Party (Note 1)	Maximum Amount Endorsed/ Guaranteed During the Period (Note 3)	Outstanding Endorsement/ Guarantee at the End of the Period (Notes 2 and 3)	Actual Amount Borrowed (Note 3)	Amount Endorsed/ Guaranteed by Collateral	Ratio of Accumulated Endorsement/ Guarantee to Net Equity in Latest Financial Statements (%)	Aggregate Endorsement/ Guarantee Limit (Note 1)	Endorsement/ Guarantee Given by Parent on Behalf of Subsidiaries	Endorsement/ Guarantee Given by Subsidiaries on Behalf of Parent	Endorsement/ Guarantee Given on Behalf of Companies in Mainland China
		Name	Relationship										
0	The Company	All Cosmos Industries Sdn. Bhd.	The Company directly and indirectly hold more than 50% voting share of the investee company.	\$ 1,481,562	\$ 1,080,826	\$ 1,080,826	\$ 74,498	\$ -	47.42	\$ 2,279,326	Yes	No	No

Note 1: The total amount of endorsements/guarantee provided shall not aggregate more than 100% of the Company's net asset value in its latest financial statement. The total limit on endorsement/guarantee given on behalf of each party shall not exceed 65% of the Company's net asset value in its latest financial statement.

Note 2: The transactions were eliminated in the consolidated financial statements.

Note 3: The maximum amount for the period, the ending balance for the period and the actual borrowing amount were translated at the exchange rate at the end of the reporting period.

ALL COSMOS BIO-TECH HOLDING CORPORATION AND SUBSIDIARIES

MARKETABLE SECURITIES HELD

JUNE 30, 2024

(In Thousands of New Taiwan Dollars, Unless Number of Shares and Shareholding Ratio Otherwise Stated)

Holding Company Name	Type and Name of Marketable Securities	Relationship with the Holding Company	Financial Statement Account	June 30, 2024				Note
				Number of Shares	Carrying Amount	Percentage of Ownership (%)	Fair Value	
The Company	<u>Stock</u> Taiwan Exosome Co., Ltd.	None	Financial assets at FVTOCI - non-current	1,905,745	\$ 4,917	1.13	\$ 4,917	Note
All Cosmos Industries Sdn. Bhd.	<u>Mutual fund</u> AHAM AHIMAN MONEY MARKET FUND	None	Financial assets at FVTPL - current	10,843,962	42,734	-	42,734	Note

Note: There is no restriction due to collateral, pledge loan or other arrangement of the reporting period.

ALL COSMOS BIO-TECH HOLDING CORPORATION AND SUBSIDIARIES

TOTAL PURCHASES FROM OR SALES TO RELATED PARTIES AMOUNTING TO AT LEAST \$100 MILLION OR 20% OF THE PAID-IN CAPITAL FOR THE SIX MONTHS ENDED JUNE 30, 2024

(In Thousands of New Taiwan Dollars, Unless Stated Otherwise)

Buyer/Seller	Related Party	Relationship	Transaction Details				Abnormal Transaction		Notes/Accounts Receivable (Payable)		Note
			Purchase/Sale	Amount	% to Total	Payment Terms	Unit Price	Payment Terms	Ending Balance	% to Total	
All Cosmos Industries Sdn. Bhd.	PT All Cosmos Indonesia	The company has same ultimate parent company	Sale	\$ (148,149)	(24)	120 days	NA (Same as the Group's usual list prices)	NA (Same as the Group's usual terms)	\$ 129,646	43	Note
Sabah Softwoods Hybrid Fertiliser Sdn. Bhd.	Sabah Softwoods Berhad	Substantive related party	Sale	(169,765)	(59)	60 days	NA (Same as the Group's usual list prices)	NA (Same as the Group's usual terms)	39,546	39	

Note: The transactions were eliminated in the consolidated financial statements.

ALL COSMOS BIO-TECH HOLDING CORPORATION AND SUBSIDIARIES

RECEIVABLES FROM RELATED PARTIES AMOUNTING TO AT LEAST NT\$100 MILLION OR 20% OF THE PAID-IN CAPITAL

JUNE 30, 2024

(In Thousands of New Taiwan Dollars)

Company Name	Related Party	Relationship	Ending Balance (Note)	Turnover Rate	Overdue		Amounts Received in Subsequent Period	Allowance for Impairment Loss
					Amount	Action Taken		
The Company	All Cosmos Industries Sdn. Bhd.	Ultimate parent company	\$ 172,317	-	\$ -	-	\$ 172,317	\$ -
All Cosmos Industries Sdn. Bhd.	PT All Cosmos Indonesia	The company has same ultimate parent company	129,646	2.94	-	-	10,164	-

Note: The transactions were eliminated in the consolidated financial statements.

ALL COSMOS BIO-TECH HOLDING CORPORATION AND SUBSIDIARIES

INTERCOMPANY RELATIONSHIPS AND SIGNIFICANT INTERCOMPANY TRANSACTIONS
FOR THE SIX MONTHS ENDED JUNE 30, 2024

(In Thousands of New Taiwan Dollars and Malaysian Ringgit)

No. (Note 1)	Investee Company	Counterparty	Relationship (Note 2)	Transactions Details				
				Financial Statement Accounts	Amount in MYR	Amount in NT\$	Payment Terms	% to Total Sales or Assets
0	The Company	All Cosmos Industries Sdn. Bhd.	a	Endorsement/guarantee	\$ 157,128	\$ 1,080,826	Cash dividend	29
			a	Investments accounted for using the equity method	25,000	172,317		5
		Sabah Softwoods Hybrid Fertiliser Sdn. Bhd.	a	Other receivables	25,000	172,317		5
			a	Investments accounted for using the equity method	2,750	18,759		-
		PT All Cosmos Biotek	a	Other receivables	2,435	16,748		-
1	All Cosmos Industries Sdn. Bhd.	PT All Cosmos Indonesia	c	Sales revenue	21,940	148,149	Sales price is based on market price and transfer pricing within the Group; payment terms is net 120 days	15
			c	Trade receivables	18,848	129,646		3
2	Arif Efektif Sdn. Bhd.	Sabah Softwoods Hybrid Fertiliser Sdn. Bhd.	c	Sales revenue	1,505	10,160	Sales price is based on market price and transfer pricing within the Group; payment terms is net 30 days	1

Note 1: Business relationship between the parent company and its subsidiaries are coded as follows:

- a. The Company (parent company) is "0".
- b. The subsidiaries are coded consecutively beginning from "1" in the order presented in the table above.

Note 2: The relationship between transaction company and counterparty is classified into the following three categories:

- a. The Company to subsidiary.
- b. Subsidiary to the Company.
- c. Subsidiary to another subsidiary.

Note 3: For balance sheet items, the percentage column shows the percentage of ending balance of the item to the consolidated total assets; for income statement items, this column shows the percentage of the accumulated amount of the transactions in the reporting period to the consolidated total operating revenue for the reporting period.

Note 4: Except for investments accounted for using the equity method recognized at the historical exchange rate, all assets and liabilities for the six months ended June 30, 2024 were translated at the exchange rate (MYR1=NT\$6.878643) at the end of the reporting period. All net income statement items were translated at the average exchange rate (MYR1=NT\$6.752541).

Note 5: The transactions were eliminated in the consolidated financial statements.

Note 6: This table discloses significant transactions with amounts of at least NT\$10,000 thousand.

ALL COSMOS BIO-TECH HOLDING CORPORATION AND SUBSIDIARIES

INFORMATION ON INVESTEEES
FOR THE SIX MONTHS ENDED JUNE 30, 2024
(In Thousands of New Taiwan Dollars, Unless Stated Otherwise)

Investor Company	Investee Company	Location	Main Businesses and Products	Original Investment Amount		As of June 30, 2024			Net Income (Loss) of the Investee	Share of Profit (Loss)	Note
				June 30, 2024	December 31, 2023	Number of Shares	%	Carrying Amount			
The Company	All Cosmos Industries Sdn. Bhd.	Johor Bahru, Malaysia	Manufacturing and sales of Bio-organic and Bio-chemical compound fertilizers	\$ 292,969 (MYR 30,000)	\$ 292,969 (MYR 30,000)	30,000,000	100	\$ 1,657,462 (MYR 240,958)	\$ 191 (MYR 28)	\$ -8,918 (MYR -1,321)	Notes 1 and 2
	Sabah Softwoods Hybrid Fertiliser Sdn. Bhd.	Lahad Datu, Malaysia	Manufacturing and sales of Bio-organic and Bio-chemical compound fertilizers	292,053 (MYR 33,000)	292,053 (MYR 33,000)	33,000,000	55	475,272 (MYR 69,094)	33,595 (MYR 4,975)	18,477 (MYR 2,736)	Notes 1 and 3
	PT All Cosmos Indonesia	North Sumatra, Indonesia	Sales of Bio-organic and Bio-chemical compound fertilizers	9,925 (IDR 3,960,000)	9,925 (IDR 3,960,000)	79,200	99	84,483 (MYR 12,282)	-1,921 (MYR -285)	-1,902 (MYR -282)	Note 1
	PT All Cosmos Biotek	North Sumatra, Indonesia	Manufacturing and sales of Bio-organic and Bio-chemical compound fertilizers	241,765 (IDR108,640,000)	241,765 (IDR108,640,000)	108,640	83	207,751 (MYR 30,202)	-4,169 (MYR -617)	-3,480 (MYR -515)	Note 1
	GK Bio International Sdn. Bhd.	Kuala Lumpur, Malaysia	Wholesale of probiotics	26,048 (MYR 3,600)	26,048 (MYR 3,600)	3,600,000	60	119,666 (MYR 17,397)	33,160 (MYR 4,911)	19,896 (MYR 2,946)	Note 1
All Cosmos Industries Sdn. Bhd.	PT All Cosmos Indonesia	North Sumatra, Indonesia	Sales of Bio-organic and Bio-chemical compound fertilizers	102 (IDR 40,000)	102 (IDR 40,000)	800	1	92 (MYR 13)	-1,921 (MYR -285)	-19 (MYR -3)	Note 1
	Arif Efektif Sdn. Bhd.	Johor Bahru, Malaysia	Research and development of effective microorganisms for Bio-organic and Bio-chemical compound fertilizers	2,349 (MYR 245)	2,349 (MYR 245)	245,000	49	35,598 (MYR 5,175)	-898 (MYR -133)	52 (MYR 8)	Notes 1 and 2
	Kinabalu Life Sciences Sdn. Bhd.	Lahad Datu, Malaysia	Research and development of effective microorganisms for waste disposal of oil-palm	17,559 (MYR 2,400)	17,559 (MYR 2,400)	2,400,000	60	20,117 (MYR 2,925)	276 (MYR 41)	166 (MYR 25)	Notes 1
	Cosmos Nutriscience Sdn. Bhd. (formerly known as Cosmos Biowood Sdn. Bhd.)	Johor Bahru, Malaysia	Manufacturing and sales of health care food and research and development biotechnology	8,457 (MYR 1,200)	8,457 (MYR 1,200)	1,200,000	92	-1,190 (MYR -173)	-4,164 (MYR -617)	-3,844 (MYR -569)	Note 1
	Eastern Eckare Malaysia Sdn. Bhd.	Kuala Lumpur, Malaysia	Sales of health care food and cosmetics	30,724 (MYR 4,500)	30,724 (MYR 4,500)	4,500,000	60	21,989 (MYR 3,197)	-14,232 (MYR -2,108)	-8,539 (MYR -1,265)	Note 1
Sabah Softwoods Hybrid Fertiliser Sdn. Bhd.	Sawit Ecoshield Sdn. Bhd.	Lahad Datu, Malaysia	Manufacturing and sales of biological vaccines	14,788 (MYR 2,000)	14,788 (MYR 2,000)	2,000,000	40	24,226 (MYR 3,522)	3,249 (MYR 481)	1,255 (MYR 186)	

Note 1: The transactions were eliminated in the consolidated financial statements.

Note 2: Realized/unrealized gross profit on intercompany transactions were included in the carrying amount and share of profit or loss.

Note 3: A subsidiary with a material non-controlling interest.

TABLE 8**ALL COSMOS BIO-TECH HOLDING CORPORATION AND SUBSIDIARIES****INFORMATION OF MAJOR SHAREHOLDERS****JUNE 30, 2024**

Name of Major Shareholder	Shares	
	Number of Shares	Percentage of Ownership (%)
All Cosmos Investment Ltd.	22,500,001	35.13
Oil Palm Plantation Ltd.	7,500,000	11.71
Maxtrength Corp.	4,500,000	7.02
CHEN, PIN-WEN	4,451,000	6.95

Note: The information of major shareholders presented in this table is provided by the Taiwan Depository & Clearing Corporation based on the number of ordinary shares held by shareholders with ownership of 5% or greater, that have been issued without physical registration (including treasury shares) by the Company as of the last business day for the current quarter. The share capital in the consolidated financial statements may differ from the actual number of shares that have been issued without physical registration because of different preparation basis.